AU2006274507B2

AU2006274507B2 - Method for the detection and/or identification of a microorganism

Info

Publication number: AU2006274507B2
Application number: AU2006274507A
Authority: AU
Inventors: Benjamin Nicholas Fry; Viraj Navagamuwa Perera
Original assignee: Diagnostic Array Systems Pty Ltd
Current assignee: Diagnostic Array Systems Pty Ltd
Priority date: 2005-07-27
Filing date: 2006-07-27
Publication date: 2013-08-29
Anticipated expiration: 2026-07-27
Also published as: AU2006274507A1; AU2006274507A2

Abstract

The present invention relates generally to a method of identifying micro-organisms in a sample and in particular to the identification of prokaryotic micro-organisms. In some embodiments, the present invention relates to a method for the detection and/or identification of at least one microorganism or for the simultaneous detection and/or identification of several microorganisms in a test sample wherein the test sample is contacted with one or more probes derived from a tuf gene variable region.

Description

WO 2007/012131 PCT/AU2006/001056 -1 METHOD FOR THE DETECTION AND/OR IDENTIFICATION OF A MICROORGANISM FIELD 5 The present invention relates generally to a method of identifying micro-organisms in a sample and in particular to the identification of prokaryotic micro-organisms. The method of the present invention is useful, inter alia, for 10 the prognosis, diagnosis, prevention, and treatment of diseases associated with pathogens (including human pathogens) and in particular to diseases such as respiratory infections, gastrointestinal tract infections, dermal infection, genital tract infections and nosocomial 15 infections. The present invention also relates to kits used for identifying micro-organisms, particularly prokaryotic micro-organisms. BACKGROUND 20 Currently, the standard method used for the diagnosis of bacterial infections is the culture of clinical samples obtained from patients. Culture techniques have been used for many years for clinical diagnosis. Apart from being 25 slow, time-consuming and labour intensive, the reliability of results obtained by culture techniques is very low. Consequently, this has hindered the prescription of effective drugs for treating bacterial infections, resulting in more patient suffering and/or death. 30 Other shortcomings of present methods of microbial identification include the need for special growth media, the inability to distinguish between closely related species and strains, and the need for large amounts of 35 sample. Importantly, previous methods of microbial detection have found it difficult to simultaneously detect more than one micro-organism in a sample. Consequently, 2 there is a need to develop methods of identifying microorganisms in samples which are rapid, sensitive and accurate. 5 SUMMARY Accordingly, in a first aspect the invention provides a method for detecting at least one microorganism in a clinical sample comprising: io (a) providing a clinical sample suspected of containing one or more microorganisms; (b) releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) from said clinical sample, if present in the clinical 15 sample; (c) amplifying a portion of said polynucleic acids with at least one primer pair selected from SEQ ID NO: 394 and 395 or SEQ ID NO: 396 and 395 to produce an amplified product; 20 (d) contacting said amplified product with at least one probe or combination thereof selected from the group consisting of SEQ ID NOs:12 to 393 for a time and under conditions sufficient for hybridization to take place; and 25 (e) detecting any hybridization which has taken place in step (d); wherein the presence or absence of hybridization is indicative of the presence or absence of said one or more microorganisms in said clinical sample. 30 It is preferable that the polynucleic acid in said test sample is amplified, for example, using an amplification technique such as polymerase chain reaction (PCR). 35 Accordingly, in a second aspect the present invention provides a method for the detection and/or identification of at least one microorganism or for the simultaneous detection and/or identification of several microorganisms 3740347_1 DOCX- WO 2007/012131 PCT/AU2006/001056 -3 in a test sample comprising: (a) optionally, releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) to be detected; 5 (b) optionally, amplifying at least a portion of a tuf gene variable region from said microorganism(s) with at least one primer pair; (c) contacting said test sample or said polynucleic acid from said test sample with one or more 10 probes derived from said tuf gene variable region for a time and under conditions sufficient for hybridization to take place; and (d) detecting any hybridization which has taken place in step (c); 15 wherein the presence or absence of hybridization is indicative of the presence or absence of said one or more said microorganisms in said test sample. In some embodiments the polynucleic acid is derived from a 20 tuf gene variable region as shown in SEQ ID NOs.:1 to 11. Preferably, the polynucleic acid consists essentially of nucleotides 108-220, 393-591, 708-774, 792-816, and/or 885-945 of SEQ ID NOs.:1 to 11. 25 In other embodiments the polynucleic acid has a sequence which is antisense to a tuf gene variable region as shown in SEQ ID NOs.:1 to 11. Preferably, the polynucleic acid is consists essentially of nucleotides antisense to the nucleotides 108-220, 393-591, 708-774, 792-816, and/or 30 885-945 of SEQ ID NOs.:1 to 11. In some embodiments, the step of contacting the test sample comprises hybridization with at least a portion of a tuf gene variable region with a set of probes comprising 35 at least one probe selected from the group consisting of SEQ ID NOs:12 to 84, 208 to 251, 254-315 and 330 to 393.

WO 2007/012131 PCT/AU2006/001056 -4 Accordingly, in a third aspect the present invention provides a method for the detection and/or identification of at least one microorganism or for the simultaneous detection and/or identification of several microorganisms 5 in a test sample comprising: (a) optionally, releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) to be detected; (b) optionally, amplifying at least a portion 10 of a tuf gene variable region from said microorganism(s) with at least one primer pair; (c) hybridizing at least a portion of a tuf gene variable region from said microorganism(s) with a set of probes comprising at least one probe selected from the 15 group consisting of SEQ ID NOs: 12 to 84, 208 to 251, 254 315 and 330 to 393; (d) detecting hybrids formed in step (c); and (e) identifying said at least one microorganism from said detecting of step (d). 20 In other embodiments, the at least one probe is selected from the group consisting of SEQ ID NOs: 12 to 84, 208 to 315 and 330 to 393. In other embodiments, the at least one probe is selected from the group consisting of SEQ ID 25 NOs:12 to 392 and 393. In a fourth aspect, the present invention provides a method for the diagnosis and/prognosis of a disease associated with a target microorganism comprising: 30 (a) optionally, releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) to be detected; (b) optionally, amplifying at least a portion of a tuf gene variable region from said microorganism(s) 35 with at least one primer pair; (c) contacting said test sample or said polynucleic acid from said test sample with one or more WO 2007/012131 PCT/AU2006/001056 -5 probes derived from said tuf gene variable region for a time and under conditions sufficient for hybridization to take place; and (d) detecting any hybridization which has taken 5 place in step (c); wherein the presence or absence of hybridization is indicative of the presence or absence of the target microorganism in said test sample; (e) associating the presence of said one or 10 more said target microorganisms with a disease; and (f) determine diagnosis and/or prognosis for said disease. In a fifth aspect, the present invention provides a method 15 for the prevention or treatment of a disease associated with a target microorganism comprising: (a) optionally, releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) to be detected; 20 (b) optionally, amplifying at least a portion of a tuf gene variable region from said microorganism(s) with at least one primer pair; (c) contacting said test sample or said polynucleic acid from said test sample with one or more 25 probes derived from said tuf gene variable region for a time and under conditions sufficient for hybridization to take place; and (d) detecting any hybridization which has taken place in step (c); 30 wherein the presence or absence of hybridization is indicative of the presence or absence of the target microorganism in said test sample; (e) associating the presence of said one or more said target microorganisms with a disease; and 35 (f) prescribing prevention or treatment of said disease.

WO 2007/012131 PCT/AU2006/001056 -6 In some embodiments, the step of associating the presence of one or more target microorganisms with -a disease or the step of prescribing a treatment comprise the step of using a computer program. 5 In some embodiments, the disease may be a bacterial infection, respiratory infection, gastrointestinal tract infection, dermal infection, bloodstream infection, meningitis or central nervous system infection, urinary 10 tract infection, genital tract infection, wound infection, or nosocomial infection. In some embodiments, the microorganism detected and/or identified is selected from the group consisting of 15 Bordetella species, Chlamydophila species, Haemophilus species, Legionella species, Mycoplasma species, Mycobacterium'species, Staphylococcus species, Streptococcus species, Pseudomonas species, Moraxella species and Fusobacterium species, Stenotrophomonas 20 species, Burkholderi species, Enterococcus species, Corynebacterium species and Neisseria species. In some embodiments, the step of amplifying at least a portion of a tuf gene variable region from the 25 microorganism(s) utilizes at least one primer pair, wherein at least one of the primers is selected from the group consisting of SEQ ID NOs:394-396, or equivalents thereof, provided said equivalents specifically amplify the tuf variable region or a part thereof of different 30 species of microorganism at the same time. In a sixth aspect, the present invention provides a composition comprising at least one probe selected from the group consisting of SEQ ID NOs:12-393 or equivalents 35 thereof, provided that said equivalents specifically bind to a tuf gene variable region of a microorganism to be detected.

WO 2007/012131 PCT/AU2006/001056 -7 In a seventh aspect, the present invention provides a composition comprising at least one primer selected from the group consisting of SEQ ID NOs:394-396, or equivalents 5 thereof, provided said equivalents specifically amplify the tuf gene variable region or a part thereof of a microorganism to be detected. In an eighth aspect, the present invention provides an 10 oligonucleotide probe for the detection and/or identification of at least one microorganism found in test sample selected from the group consisting of Bordetella species, Chlamydophila species, Haemophilus species, Legionella species, Mycoplasma species, 15 Mycobacterium species, Staphylococcus species, Streptococcus species, Pseudomonas species, Moraxella species and Fusobacterium species, Stenotrophomonas species, Burkholderi species, Enterococcus species, Corynebacterium species and Neisseria species, wherein 20 said probe is selected from the group consisting of: for Haemophilus influenzae: TATTATCCGTACAGGTGATGAAGTAGAAA (SEQ ID NO. :12); 25 AAAGATACAGCGAAAACTACTGTAACG (SEQ ID NO. :13); CATCGGTGCATTATTACGTGGTAC (SEQ ID NO.:14); CATACTCCATTCTTCAAAGGTTACCG (SEQ ID NO. :15); TGACTGGTACAATCGAATTACCAGAA (SEQ ID NO. :16); CCGTAAATTACTTGACGAAGGTCG (SEQ ID NO. :17); 30 ACTTCGAATC AGAAGTGTAC (SEQ ID NO. : 64); CAAACGTGAA GAAATCGAAC (SEQ ID NO. :65); CGATAACATC AAGATGACAG T (SEQ ID NO. :66); for Moraxella catarrhalis: 35 TGAGCGTGACATCGATAAGTCA (SEQ ID NO. :18); CAGGCATTATTAAAGTTGGTGATGAAATT (SEQ ID NO. :19); WO 2007/012131 PCT/AU2006/001056 -8 AAACCAACTACTAAAACCACTTGTACTG (SEQ ID NO. :20); CGTAAGCTGCTAGACGAAGGT (SEQ ID NO.:21); TACCCCATTCCTAAATGGCTATCG (SEQ ID NO. :22); TAACTGGTGCCATCACCCTAC (SEQ ID NO. :23); 5 AGTTTGATGCAGAAGTATACG (SEQ ID NO. :208) TATCCTACTACGTGGTACTAA (SEQ ID NO. :209) ATAACGTTGAGATGAGCG (SEQ ID NO. :210) for Enterococcus faecalis: 10 AAGGCGACGAGTCTTATGAAGA (SEQ ID NO. :24); AATTAATGGCTGCAGTTGACGAAT (SEQ ID NO. :25); GAAGTTCGCGTTGGTGACG (SEQ ID NO.:26); GACGAAACATCTAAAACAACTGTTACAG (SEQ ID NO. :27); 15 TGGTGTTGTAGAATTGCCAGAAG (SEQ ID NO. :28); TAAACCAGCTACAATCACTCCACA (SEQ ID NO. :29); for Staphylococcus aureus: 20 GTTGACATGGTTGACGATGAAGAATTA (SEQ ID NO.:30); CTTAGAATTAATGGAAGCTGTAGATACTTACA (SEQ ID NO. :31); ATCATCGGTTTACATGACACATCTAAAA (SEQ ID NO. :32); CACCACATACTGAATTTAAAGCAGAAGTA (SEQ ID NO. :33); CATTCTTCTCAAACTATCGTCCACAA (SEQ ID NO. :34); 25 CTGGTGTTGTTCACTTACCAGAAG (SEQ ID NO. :35); TACTGAAATGGTAATGCCTGGTGATA (SEQ ID NO. :36); CCAATCGCGATTGAAGACGG (SEQ ID NO. :37); CTGGTTCAGCATTAAAAGCTTTAGAAG (SEQ ID NO. :38); TGACAACATTGGTGCATTATTACGT (SEQ ID NO. :39); 30 TGTTACAGGTGTTGAAATGTTCCG (SEQ ID NO. :40); GTATTATCAAAAGACGAAGGTGGACG (SEQ ID NO. :41); GCGATGCTCAATACGAAGAAAAAATC (SEQ ID NO. :42); TGAATTCAAA GCAGAAGTAT AC (SEQ ID NO. :76); ATTATTACGT GGTGTTGCTC (SEQ ID NO. :77); 35 GTGATAACGT TGAAATGACA G (SEQ ID NO. :78); for Staphylococcus epidermidis: WO 2007/012131 PCT/AU2006/001056 TAGACTTAATGCAAGCAGTTGATGATTAC (SEQ ID NO. :43); CCACACACAAAATTCAAAGCTGAAG (SEQ ID NO. :44); CTGGTGTTGTAAACTTACCAGAAGG (SEQ ID NO. :45); 5 GAAATGGTTATGCCTGGCGAC (SEQ ID NO. :46); CTGGTTCTGCATTAAAAGCATTAGAAG (SEQ ID NO. :47); TGACAACATCGGTGCTTTATTACG (SEQ ID NO. :48); CTGTTACTGGTGTAGAAATGTTCCG (SEQ ID NO. :49); CGTATTATCTAAAGATGAAGGTGGACG (SEQ ID NO. :50); 10 for Pseudomonas aeruginosa: AAGTTCGAGTGCGAAGT (SEQ ID NO. :51); AAGGCGTAGAGATGGTAAT (SEQ ID NO. :52); 15 TTCTTCAAGGGCTACCG (SEQ ID NO. :53); ATCATCAAGGTCCAGGAAGAAGT (SEQ ID NO. :54); ACCAAGACTACCTGCACCG (SEQ ID NO. :55); TGTACGTGCTGTCCAAGGAA (SEQ ID NO. :56); CCGGTAACTGCGAACTGC (SEQ ID NO. :57); 20 CACGTTGACTGCCCCGGTCACGC (SEQ ID NO. :85); ACGCCTTCCGGCAGTTCGCAGTTAC (SEQ ID NO. :86); ATCGGTCACGTTGACCATGGCA (SEQ ID NO. :87); GCCGCCTTCGCGGATCGCGAA (SEQ ID NO. :88); 25 for Bordetella pertussis: GTACATTCTG TCCAAGGAAG (SEQ ID NO. :58); GACAACGTGG GTATCTTG (SEQ ID NO. :59); GACAAGGAAA TGGTGCT (SEQ ID NO. :60); 30 for Chlamydophila pneumoniae: AATTTAAGTC AGCTGTTTAC G (SEQ ID NO. :61); GAGGTATTGG AAAGAACGAT (SEQ ID NO.:62); 35 ATAACGTTGA GCTTGATGTT (SEQ ID NO. :63); for Legionella pneumophila: WO 2007/012131 PCT/AU2006/001056 -10 AGTTTGAAGC AGAAGTGTAT (SEQ ID NO. :67); TGTTATTACG AGGTACGAAG (SEQ ID NO. :68); AGATAATGTG CAATTAGTTG TTA (SEQ ID NO. :69); 5 for Mycoplasma pneumoniae: GAAATTTAAA GCGGAAATCT ATG (SEQ ID NO. :70); GAACGTGGTC AAGTGTTAG (SEQ ID NO. :71); 10 GACAATACCT CGATTACAGT (SEQ ID NO. :72); for Mycobacterium tuberculosis AACATCTCGG TGAAGTTGAT (SEQ ID NO. :73); TGACAACACC AACATCTC (SEQ ID NO. :74); 15 ACGAAGGTCT GCGTTT (SEQ ID NO. :75); for Streptococcus pneumoniae AATTCAAAGG TGAAGTCTAC A (SEQ ID NO. :79); 20 CAACGTGATG AAATCGAAC (SEQ ID NO. :80); GACAATCGAC GTTGAGTT (SEQ ID NO. :81); for Streptococcus pyogenes 25 CAAAGGTGAA GTATATATCC TTTC (SEQ ID NO. :82); CAACGTGACG AAATCGAA (SEQ ID NO. :83); CGTGACAATC AACGTTGA (SEQ ID NO. :84); and combinations thereof. 30 In a ninth aspect, the present invention provides a method of hybridization comprising contacting a test sample suspected of containing a polynucleic acid with a solid support, which has immobilized thereon one or more probes 35 selected from the group consisting of SEQ ID NOs: 12-392 and 393.

WO 2007/012131 PCT/AU2006/001056 -11 In some embodiments, certain aspects of the invention are provided as kits. Accordingly, in a tenth aspect, the present invention 5 provides a kit for the detection and/or identification of at least one microorganism or the detection and/or identification of several microorganisms simultaneously in a test sample, comprising (a) optionally, at least one primer pair 10 allowing amplification of at least a portion of a tuf gene variable region; (b) the composition according to the sixth aspect; (c) a buffer, or components necessary to 15 produce the buffer enabling a hybridization reaction between the probe(s) contained in said composition and a polynucleic acid present in the sample, or the amplified products thereof; (d) a solution, or components necessary for 20 producing the solution, enabling washing of the hybrids formed under the appropriate wash conditions; (e) optionally, a means for detecting the hybrids resulting from the preceding hybridization. 25 In an eleventh aspect, the present invention provides a method for the detection and/or identification of at least one microorganism or for the simultaneous detection and/or identification of several microorganisms in a sputum sample comprising the steps of 30 (a) optionally, releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) to be detected; (b) optionally, amplifying at least a portion of a tuf gene variable region from said microorganism(s) 35 with at least one primer pair; (c) hybridizing at least a portion of a tuf gene variable region from said microorganism(s) with a set WO 2007/012131 PCT/AU2006/001056 -12 of probes comprising at least one probe selected from the group consisting of SEQ ID NOs: 12 to 84, 208 to 251, 254 315 and 330 to 393; (d) detecting hybrids formed in step (c); 5 (e) identifying said at least one microorganism from said detecting of step (d). In a twelfth aspect, the present invention provides a microarray comprising at least one probe selected from the 10 group consisting of SEQ ID NOs: 12-393 or equivalents thereof, provided that said equivalents specifically bind to the tuf gene variable region of a microorganism. BRIEF DESCRIPTION OF THE FIGURES 15 Figure 1 is a PCR amplification of the tuf gene fragment. Lane 1, DNA standard marker; lane 2, Streptococcus pneumoniae; Lane 3, Moraxella catarrhalis; Lane 4, Legionella pneumophila; Lane 5, Staphylococcus aureus; 20 Lane 6, Haemophilus influenzae. Figure 2 shows the detection of Streptococcus pneumoniae. Tests 1, 2 and 3-positive test results in duplicate indicating the presence of Streptococcus pneumoniae, one 25 of the causative agents of bacterial pneumonia. Test 1 - SEQ ID NO.:79 Test 2 - SEQ ID NO.:80 Test 3 - SEQ ID NO.:81 30 Figure 3 shows the detection of Moraxella catarrhalis. Tests 1, 2 and 3-positive test results in duplicate indicating the presence of Moraxella catarrhalis, one of the causative agents of chronic obstructive pulmonary disease. 35 Test 1 - SEQ ID NO.:208 Test 2 - SEQ ID NO.:209 Test 3 - SEQ ID NO.:210 WO 2007/012131 PCT/AU2006/001056 - 13 Figure 4 shows the detection of Legionella pneumophila. Tests 1, 2 and 3-positive test results in duplicate indicating the presence of Legionella pneumophila, the 5 main causative agent of Legionnaire's disease. Test 1 - SEQ ID NO.:67 Test 2 - SEQ ID NO.:68 Test 3 - SEQ ID NO.:69 10 Figure 5 shows the detection of Staphylococcus aureus. Tests 1, 2 and 3-positive test results in duplicate indicating the presence of Staphylococcus aureus, one of the causative agents of soft tissue infections and pneumonia in the elderly. 15 Test 1 - SEQ ID NO.:76 Test 2 - SEQ ID NO.:77 Test 3 - SEQ ID NO.:78 Figure 6 shows the detection of Haemophilusinfluenzae. 20 Tests 1, 2 and 3, positive test results in duplicate indicating the presence of Haemophilus influenzae, one of the causative agents of bacterial pneumonia. Test 1 - SEQ ID NO.:64 Test 2 - SEQ ID NO.:65 25 Test 3 - SEQ ID NO.:66 DETAILED DESCRIPTION Before describing preferred embodiments in detail, it is 30 to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only and is not intended to be limiting. All publications, patents and patent applications cited 35 herein, whether supra or infra, are hereby incorporated by reference in their entirety. However, publications mentioned herein are cited for the purpose of describing WO 2007/012131 PCT/AU2006/001056 -14 and disclosing the protocols and reagents which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not 5 entitled to antedate such disclosure by virtue of prior invention. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of 10 microbiology and molecular biology which are within the skill of the art. Such techniques are described in the literature. See, for example, Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); "Molecular Cloning: A 15 Laboratory Manual", 2 nd Ed., (ed. by Sambrook, Fritsch and Maniatis) (Cold Spring Harbor Laboratory Press: 1989); "Nucleic Acid Hybridization", (Hames & Higgins eds. 1984); "Oligonucleotide Synthesis" (Gait ed., 1984); Remington's Pharmaceutical Sciences, 17 th Edition, Mack Publishing 20 Company, Easton, Pennsylvania, USA.; "The Merck Index", 12 th Edition (1996), Therapeutic Category and Biological Activity Index; and "Transcription & Translation", (Hames & Higgins eds. 1984). 25 It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a micro organism" includes a plurality of microorgansims and "a 30 nucleic acid molecule" refers to a plurality of nucleic acid molecules, and so forth. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly 35 understood by one of ordinary skill in the art to which this invention belongs.

WO 2007/012131 PCT/AU2006/001056 - 15 In the description that follows, if there is no instruction, it will be appreciated that cell culture techniques are well-known in this field and any such technique may be adopted. 5 Although any materials and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred materials and methods are now described. 10 By "comprising" is meant including, but not limited to, whatever follows the word comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are 15 optional and may or may not be present. By "consisting of" is meant including, and limited to, whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and that no other elements may be present. By 20 "consisting essentially of" is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially 25 of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements. 30 In work leading up to the present invention, the inventors discovered that the tuf gene contained variable region which differed between different microorganisms and therefore could be used to identify different microorganisms. Different microorganisms in a test sample 35 can be identified by detecting hybridization between the variable region and a probe specific for the variable region.

WO 2007/012131 PCT/AU2006/001056 -16 Therefore, the present invention relates to polynucleic acid derived from a tuf gene variable region. As used herein, a "gene" is a polynucleic acid molecule that 5 contains the information for a specific function, such as the sequence encoding a specific protein. Genes may also comprise non-coding information, such as one or more of a signal sequence, an origin of replication, an enhancer element, a promoter, and/or a transcription termination 10 sequence. The term "polynucleic acid" as used herein designates mRNA, RNA, cRNA, cDNA or DNA. The tuf genes are universally present in all bacteria and generally comprise uniform sequences i.e., sequence in 15 common between all species. Examples of other universal bacterial genes include the 16s ribosomal RNA, 23s ribosomal RNA, and rpoB. Examples of tuf sequences of different microorganisms are set out in SEQ ID Nos.: 1 to 11. 20 It will be appreciated by those skilled in the art that the sequences disclosed herein may vary from the sequences provided in any of SEQ ID NOs.:1 to 11, without departing from the invention. In particular, the tuf gene sequence 25 might vary by up to 30%, provided that a biological activity of the variant is retained. Specifically, the variant must have a variable region which can be used to identify a target microorganism. 30 A "tuf gene variable region" is those nucleotide sequences which vary in the tuf gene between species, subspecies, and substrains of a microorganism. In some embodiments, the tuf gene variable region consists essentially of nucleotides 108-220, 393-591, 708-774, 792-816, and/or 35 885-945 of SEQ ID NOs.:1 to 11. In some embodiments, the tuf gene variable region is from WO 2007/012131 PCT/AU2006/001056 -17 Berkholderia cepacia, which can be used to specifically identify this species in sputum samples of patients with cystic fibrosis. In some embodiments, one or more of SEQ ID Nos.:269 to 275, which correspond to tuf gene variable 5 region of Berkholderia cepacia, can be used. In other embodiments, the tuf gene variable region is from the tuf gene of Stenotrophomonas maltophilia, which can be used to specifically identify this species in sputum 10 samples of patients with pneumonia subsequent to a Pseudomonas aeruginosa infection. In some embodiments, one or more of SEQ ID NO.:264 to 268, which correspond to tuf gene variable regions of Stenotrophomonas maltophilia, can be used. 15 As used herein, a polynucleic acid comprises at least some part of a tuf gene including a tuf gene variable region or is derived from a tuf gene. The polynucleic acid sequence may have the nucleotide sequence of an entire tuf gene per 20 se or a part thereof as long as it contains at least one tuf gene variable region or part thereof. The polynucleic acid may also be antisense to the tuf gene. In the present invention, the term "antisense" is used to denote a nucleic acid molecule which is DNA or RNA with a 25 complementary sequence to the tuf gene variable region of the gene. According to the invention the tuf gene variable region is used to identify a target micro-organism in a test sample. 30 The test sample may be any type of sample suspected of containing a target micro-organism. Consequently, test samples for analysis by the methods of the present invention may be obtained from numerous sources. Such sources include, but are not limited to, samples derived 35 from animal subjects such as humans; flowers; seeds, vegetables; food; and samples derived from the environment. In some embodiments, the test sample is a WO 2007/012131 PCT/AU2006/001056 -18 "biological sample". Reference to a "biological sample" should be understood as a reference to any sample of biological material derived from an animal such as, but not limited to, blood, saliva, urine, tears, sweat, 5 cerebrospinal fluid, lymph fluid, serum, plasma, mucus, sputum, faeces, and biopsy specimens. The biological sample which is tested according to the methods of the present invention may be tested directly or 10 may require some form of treatment prior to testing. For example, a biopsy sample may require homogenisation prior to testing. Further, to the extent that the biological sample is not in liquid form, (for example it may be a solid, semi-solid or dehydrated liquid sample) it may 15 require the addition of a reagent, such as a buffer to mobilise the sample. The test sample may also require processing to release any polynucleic acid prior to testing. For example, the 20 polynucleic acid can be released using a lysis buffer, such as a commercially available lysis solution. A suitable commercially available lysis solution for bacteria is the Lyse-N-Gom (Pierce Biotechnology Inc, Rockford IL, USA) PCR reagent. Once released the 25 polynucleic acid is available for testing by the methods of the invention. Alternatively or in addition the test sample may be subjected to a purification step such that the polynucleic 30 acid in the test sample is isolated, concentrated or seperated. An "isolated" polynucleic acid is one which has been released and/or separated and/or recovered from a 35 component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with identification of a target WO 2007/012131 PCT/AU2006/001056 -19 micro-organism and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, a polynucleic acid will be purified and/or concentrated (1) to a degree sufficient to obtain at least 5 30 to 45 bases of nucleotide sequence information, and/or (2) to homogeneity by gel electrophoresis. In isolating the polynucleic acid the test sample may be subjected to a number of different processing steps, such 10 as tissue homogenation, cell isolation and cytoplasmic extraction, nucleic acid extraction and the like. Methods of isolating nucleic acids from cells, tissues, organs or whole organisms are known to those of ordinary skill in the art and are described, for example, in Maniatis et al. 15 (Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press, 1989) and in Ausubel et al, (Current Protocols in Molecular Biology, John Wiley & Sons, Inc 1998), the content of each are incorporated herein by reference. 20 In some embodiments of the invention, a cell from a test sample may be used as a source of polynucleic acid for analysis, thereby obviating requirements for purified cultures. The polynucleic acid molecules may be either 25 DNA, RNA or a combination of both. In some embodiments the polynucleic acid is DNA. Preferably, there is at least 100 micrograms of DNA available for analysis; however, considerably smaller amounts of DNA may be used in the methods of the invention. Nucleic acid amplification 30 techniques, such as PCR, may be used to compensate when only low levels of polynucleic acid is available for analysis. Based on sequence analysis of the target polynucleic acid, 35 a multiplex PCR reaction may be employed with the use of several primers. Multiplex PCR is the term used when more than one pair of primers is used in a polymerase chain WO 2007/012131 PCT/AU2006/001056 -20 reaction. The goal of multiplex PCR is to amplify several segments of target polynucleic acid simultaneously and thereby to conserve template polynucleic acid, time and expense. Detailed protocols for multiplex PCR can be 5 found in Molecular Cloning, A Laboratory Manual Sambrook and Russell Volume 2, third edition, Coldspring Harbour Laboratory Press. Since clinical samples often contain material that will interfere with PCR, a unique pre processing method can be developed to obtain optimum 10 amplification. The reaction conditions will be optimised for simultaneous amplification of all polynucleic acid regions of interest. Other polynucleic acid amplification techniques include 15 self-sustained sequence replication, Q beta replicase, ligation-based thermocycling approaches, real-time PCR, real-time strand displacement amplication (SDA), rolling circle amplification (RCA) and multiple-displacement amplification (MDA). 20 Detailed protocols for amplification of polynucleic acid can be found in, among other places, Ausubel et al (Short Protocols in Molecular Biology, John Wiley & Sons (1995) volume 2, 5 th edition Chapter 15) and in Sambrook and 25 Russell (Molecular Cloning, A Laboratory Manual, volume 2, third edition, Coldspring Harbour Laboratory Press). These publications also provide detailed guidance on how to design nucleic acid amplification primers. 30 In some embodiments of the present invention, the polynucleic acid is isolated and then amplified using PCR. Any amplification primers may be used to amplify tuf genes from target microorganisms as long as the primers specifically amplify the tuf gene variable region or a 35 part thereof. Designing primers that are capable of amplifying a large number of tuf genes from different species of microorganism is well within the skill in the WO 2007/012131 PCT/AU2006/001056 -21 art. For example, tuf gene sequences for bacterial species are freely available from public databases such as GenBankM. There are a number of databases capable of multiple sequence alignments using the tuf gene sequences 5 obtained. Once aligned, persons skilled in the art can determine conserved regions within the various microorganisms by analysing the multiple sequence alignment data. Table 1 shows the multiple sequence alignment of a number of tuf genes from various 10 microorganisms. In some embodiments, the primers used to amplify tuf genes from a number of microorganisms are selected from the group consisting of SEQ ID NOs:394-396, or equivalents 15- thereof, provided said equivalents specifically amplify the tuf variable region or a part thereof of different species of microorganism at the same time. The ability to design equivalents of SEQ ID NOs:394-395 is 20 well within the skill in the art. For example, it is well appreciated that the 3' end of any amplification primer is the most important end of any primer as this needs to properly anneal to a DNA template, for example, for primer extension to take place. Accordingly, the 3' ends of SEQ 25 ID NOs:394-395 need to be maintained. However, it is further appreciated that the 5' ends of most primers can be altered, extended and/or shortened without adversely affecting the primers ability to amplify a product. Persons skilled in the art are capable of determining 30 changes that can be made in primers by routine experimentation. As mentioned above, a polynucleic acid comprising a tuf gene or tuf gene variable region may be used to identify a 35 target micro-organism in a test sample. Reference to "micro-organism" encompasses any organism that can only be observed with the aid of a microscope and includes WO 2007/012131 PCT/AU2006/001056 - 22 TABLE 1 MPNE-HF2 ------------- ATGGCAAAACAAAAGTTTGATAGATCAAAAGCTCACGTTAATATTGG 47 MPNE-M129 ------------- ATGGCAAGAGAGAAATTTGACCGATCTAAACCCCACGTTAATGTAGG 47 5 LPNE-Paris GGGAGACTTTCCGATGGCGAAGGAAAAATTTGAACGTAAGAAGCCGCACGTAAACGTGGG 60 LPNE2-DAS ----------------------------------------------------------- LPNE-Philadelphial -------------- ATGGCGAAGGAAAAATTTGAACGTAAGAAGCCGCACGTAAACGTGGG 47 LPNE-Lens ------------- ATGGCGAAGGAAAAATTTGAACGTAAGAAGCCGCACGTAAACGTGGG 47 LLON-DAS ----------------------------------------------------------- 10 FNUC-DAS ----------------------------------------------------------- CPNE-CWL029 ------------- ATGTCAAAAGAAACTTTTCAACGTAATAAGCCCCATATCAATATTGG 47 EFAE-DAS ----------------------------------------------------------- EFAE-V583 -------------ATGGCAAAAGAAAAATTTGACCGTTCTAAATCCCATGTTAACATTGG 47 SAUR-Mu50 ------------- ------------ ATGGCAAAAGAAAAATTCGATCGTTCTAAAGAACATGCCAATATCGG 47 15 SAUR-N315 ------------- ATGGCAAAAGAAAAAATTCGATCGTTCTAAAGAACATGCCAATATCGG 47 SAUR-MW2 -------------ATGGCAAAAGAAAAATTCGATCGTTCTAAAGAACATGCCAAXTATCGG 47 SAUR-MSSA476 -------------ATGGCAAAAGAAAAATTCGATCGTTCTAAAGAACATGCCAATATCGG 47 SAUR-MRSA252 -------------ATGGCAAAAGAAAAATTTGATCGTTCTAAAGAACATGCCAATATCGG 47 SEPI-12228 -------------ATGGCAAAAGAAAAATTTGATCGCTCAAAAGAACATGCCAATATTGG 47 20 SEPI-RP62A -------------ATGGCAAAAGAAAAATTTGATCGCTCAAAAGAACATGCCAATATTGG 47 SMIT-DAS ----------------------------------------------------------- SSAN-DAS ----------------------------------------------------------- SMIT-NCTC12261 ------------------ ATGGCAAAAGAAAAATACGATCGTAGTAAACCACACGTTAACATTGG 47 SPNE-R6 -------------ATGGCAAAAGAAAAATACGATCGTAGTAAACCACACGTTAACATTGG 47 25 SPYo-MiGAS ------------- ATGGCAAAAGAAAAATACGATCGTAGTAAACCCCACGTTAACATTGG 47 SMUT-DAS ----------------------------------------------------------- SMUT-UA159 ------------- ATGGCAAAAGAAAAATACGATCGTAGTAAACCACACGTTAACATTGG 47 HINF-RdKW20 ------------- ATGTCTAAAGAAAAATTTGAACGTACAAAACCGCACGTAAACGTGGG 47 MCAT-DAS ----------------------------------------------------------- 30 BPER-Tohamal ------------- -ATGGCAAAAGGCAAGTTTGAACGTACCAAGCCGCACGTGAACGTGGG 47 BPAR-12822 ------------- ATGGCAAAAGGCAAGTTTGAACGTACCAAGCCGCACGTGAACGTGGG 47 BCEP2-DAS ----------------------------------------------------------- BPSE-1710b ------------- ATGGCAAAAGAGAAGTTTGAGCGGACCAAGCCGCACGTGAACGTTGG 47 SMAL-DAS ----------------------------------------------------------- 35 PAER- PA01 ------------- GTGGCTAAGGAAAAATTCGAACGTAACAAACCGCACGTCAACGTCGG 47 KPNE-DAS ----------------------------------------------------------- MAVI-KIO ------------- GTGGCGAAGGCGAAGTTCGAGCGGACGAAGCCGCACGTCAACATCGG 47 MAVI-paratub ------------- GTGGCGAAGGCGAAGTTCGAGCGGACGAAGCCGCACGTCAACATCGG 47 MAISpig-DAS ----------------------------------------------------------- 40 MKAN-DAS ----------------------------------------------------------- MTUB-H3 7RV ------------------ GTGGCGAAGGCGAAGTTCCAGCGGACCAAGCCCCACGTCAACATCGG 47 MTUB-CDC1551 ------------- --------- GTGGCGAAGGCGAAGTTCCAGCGGACCAAGCCCCACGTCAACATCGG 47 MAVI-DAS ----------------------------------------------------------- CIDP-NCTC13129 ------------------ GTGGCAAAGGCTAAGTTCGAGCGTACCAAGCCGCACGTCAACATCGG 47 45 NMEN-MC58 ------------- ATGGCTAAGGAAAAATTCGAACGTAGCAAACCGCACGTAAACGTTGG 47 NMEN-Z2491 ------------- ATGGCTAAGGAAAAATTCGAACGTAGCAAACCGCACGTAAACGTTGG 47 NMEN-DAS ----------------------------------------------------------- MPNE-HF2 GACAATTGGACATATTGACCATGGTAAAACAACTTTAACAGCTGCAATCTGTACTTACCT 107 50 MPNE-M129 TACTATTGGCCACATTGACCACGGTAAAACAACTTTAACAGCAGCTATTTGTACTGTATT 107 LPNE-Paris CACGATTGGTCACGTAGACCATGGCAAGACGACATTGACAGCAGCTATTACAACGATTAT 120 LPNE2-DAS ----------------------------------------------------------- LPNE-Philadelphial CACGATTGGTCACGTAGACCATGGTAAGACGACATTGACAGCAGCTATTACAACGATTAT 107 LPNE-Lens CACGATTGGTCACGTAGACCATGGTAAGACGACATTGACAGCAGCTATTACAACGATTAT 107 55 LLON-DAS ----------------------------------------------------------- FNUC-DAS ----------------------------------------------------------- CPNE-CWLO29 GACGATCGGGCACGTTGACCATGGTAAAACTACGCTAACAGCGGCAATTACACGCGCGCT 107 EFAE-DAS ----------------------------------------------------------- EFAE-V583 TACTATCGGACACGTTGACCATGGTAAAACTACATTAACAGCTGCAATTGCTACTGTATT 107 60 SAUR-Mu50 TACTATCGGTCACGTTGACCATGGTAAAACAACATTAACAGCAGCAATCGCTACTGTATT 107 SAUR-N315 TACTATCGGTCACGTTGACCATGGTAAAACAACATTAACAGCAGCAATCGCTACTGTATT 107 SAUR-MW2 TACTATCGGTCACGTTGACCATGGTAAAACAACATTAACAGCAGCAATCGCTACTGTATT 107 SAUR-MSSA476 TACTATCGGTCACGTTGACCATGGTAAAACAACATTAACAGCAGCAATCGCTACTGTATT 107 SAUR-MRSA252 TACTATCGGTCACGTTGACCATGGTAAAACAACATTAACAGCAGCAATCGCTACTGTATT 107 65 SEPI-12228 TACTATCGGTCACGTTGACCATGGTAAAACAACTTTAACAGCTGCTATCGCAACTGTATT 107 SEPI-RP62A TACTATCGGTCACGTTGACCATGGTAAAACAACTTTAACAGCTGCTATCGCAACTGTATT 107 SMIT-DAS ----------------------------------------------------------- SSAN-DAS ----------------------------------------------------- CTGTATT 7 SMIT-NCTC12261 TACTATCGGACACGTTGACCACGGTAAAACTACTTTGACAGCAGCTATCACAACTGTTTT 107 70 SPNE-RG TACTATCGGACACGTTGACCACGGTAAAACTACCCTAACTGCAGCTATCACAACTGTTTT 107 SPYO-M1GAS TACAATCGGACACGTTGACCATGGTAAAACTACTTTAACAGCTGCAATCACAACTGTATT 107 WO 2007/012131 PCT/AU2006/001056 - 23 SMUT-DAS ----------------------------------------------------- CTGTACT 7 SMUT-UA159 TACTATCGGACACGTTGACCATGGTAAAACTACCTTAACTGCAGCTATCACAACTGTACT 107 HINF-RdKW20 TACAATCGGCCACGTTGACCACGGTAAAACAACTTTAACAGCAGCAATCACAACCGTATT 107 MCAT-DAS ----------------------------------------------------------- 5 BPER-Tohamal TACGATTGGTCACGTTGACCACGGCAAAACGACGTTGACGGCGGCGATCACGACGGTGCT 107 BPAR-12822 TACGATTGGTCACGTTGACCACGGCAAAACGACGTTGACGGCGGCGATCACGACGGTGCT 107 BCEP2-DAS ----------------------------------------------------------- BPSE-1710b TACGATTGGTCACGTTGACCACGGCAAGACGACGCTGACGGCAGCGATCGCGACGGTGCT 107 SMAL-DAS ----------------------------------------------- TGACAAGATCGGT 13 10 PAER-PAO1 CACCATCGGTCACGTTGACCATGGCAAGACCACTCTGACCGCTGCACTGACCAAGGTCTG 107 KPNE-DAS ----------------------------------------------------------- MAVI-X1O GACCATCGGTCACGTTGACCACGGCAAGACCACGCTGACCGCGGCTATCACCAAGGTTCT 107 MAVI-paratub GACCATCGGTCACGTTGACCACGGCAAGACCACGCTGACCGCGGCTATCACCAAGGTTCT 107 MAISpig-DAS ---------------------------------------------------------- CT 2 15 MKAN-DAS ----------------------------------------------------AAGGTCCT 8 MTUB-H37RV GACCATCGGTCACGTTGACCACGGCAAGACCACCCTGACCGCGGCTATCACCAAGGTCCT 107 MTUB-CDC1551 GACCATCGGTCACGTTGACCACGGCAAGACCACCCTGACCGCGGCTATCACCAAGGTCCT 107 MAVI-DAS ----------------------------------------------------------- NCTC13129 CACCATCGGTCACGTTGACCACGGTAAGACCACCACCACCGCTGCTATCACCAAGGTTTT 107 20 NMEN-MC58 CACCATCGGTCACGTTGACCATGGTAAAACCACCCTGACTGCCGCTTTGACTACTATTTT 107 NMEN-Z2491 CACCATCGGTCACGTTGACCATGGTAAAACCACCCTGACTGCCGCTTTGACTACTATTTT 107 NMEN-DAS ----------------------------------------------------------- MPNE - HF2 TGCAAAAAAAGGTGGTGCTAAAG--------- -CAATGAAATATGATGAAATTGATAAAGC 158 25 MPNE-M129 AGCAAAAGAAGGTAAATCAGCTG--------- -CTACTCGTTACGACCAAATCGATAAGGC 158 LPNE-Paris GGCGAAGAAATATGGTGGTACAG---------CGAAGGCGTACGATCAAATTGATGCTGC 171 LPNE2-DAS ---------- TATGGTGGTACAG--------- -CGAAGGCGTACGATCAAATTGATGCTGC 41 LPNE-Philadelphial GGCGAAGAAATATGGTGGTACAG---------CGAAGGCGTACGATCAAATTGATGCTGC 158 LPNE-Lens GGCGAAGAAATATGGTGGTACAG---------CGAAGGCGTACGATCAAATTGATGCTGC 158 30 LLON-DAS ---------GTTTGGTGGTATAG---------CAAAAGCATACGATCAGATCGATGCTGC 42 FNUC-DAS ---------------AGCTAAAA----------AAGTAGATTTTGACCAAATTGATGCTGC 36 CPNE-CWL029 ATCAGGGGATGGATTGGCCTCTT----------TCCGTGACTATAGTTCAATTGACAATAC 158 EFAE-DAS ----------------GGGAAAG---------CACAAAGCTACGATTCTATCGATAACGC 35 EFAE-V583 ATCAAAACACGGTGGCGGGGAAG --------- -CACAAAGCTACGATTCTATCGATAACGC 158 35 SAUR-Muso AGCAAAAAATGGTGACTCAGTTG--------- -CACAATCATATGACATGATTGACAACGC 158 SAUR-N315 AGCAAAAAATGGTGACTCAGTTG---------CACAATCATATGACATGATTGACAACGC 158 SAUR-MW2 AGCAAAAAATGGTGACTCAGTTG---------CACAATCATATGACATGATTGACAACGC 158 SAUR-MSSA476 AGCAAAAAATGGTGACTCAGTTG---------CACAATCATATGACATGATTGACAACGC 158 SAUR-MRSA252 AGCAAAAAATGGTGACTCAGTTG--------- -CACAATCATACGACATGATTGACAACGC 158 40 SEPI-12228 AGCTAAAAATGGTGACACTGTTG--------- -CACAATCATACGATATGATTGACAACGC 158 SEPI-RPG2A AGCTAAAAATGGTGACACTGTTG---------CACAATCATACGATATGATTGACAACGC 158 SMIT-DAS ----------------------------------AAAGACTATGCGTCTATCGATGCTGC 26 SSAN-DAS GGCACGTCGCTTGCCTTCAGCAGTTAACCAACCTAAAGACTATGCGTCTATCGATGCTGC 67 SMIT-NCTC12261 GGCACGTCGCTTGCCTTCAGCTGTTAACCAACCTAAAGACTATGCGTCTATCGATGCTGC 167 45 SPNE-R6 GGCACGTCGCTTGCCTTCATCAGTTAACCAACCTAAAGACTATGCGTCTATCGATGCTGC 167 SPYO-M1GAS GGCACGTCGCTTGCCTTCATCAGTTAACCAACCAAAAGATTACGCTTCTATCGATGCTGC 167 SMUT-DAS GGCACGTCGTCTTCCAAGTGCAGTAAACCAACCAAAAGATTATTCATCTATTGATGCTGC 67 SMUT-UA15 9 GGCACGTCGTCTTCCAAGTGCAGTAAACCAACCAAAAGATTATTCATCTATTGATGCTGC 167 HINF-RdKW20 AGCAAAACACTACGGTGGTGCAG---------CGCGTGCATTTGACCAAATTGATAACGC 158 50 MCAT-DAS --------------------------------------------------- CGACTCTGC 9 BPER-Tohamal GTCGAACAAGTTCGGCGG--------- -CGAGGCTCGCGGCTACGACCAGATTGACGCGGC 158 BPAR-12822 GTCGAACAAGTTCGGCGG---------CGAGGCTCGCGGCTACGACCAGATTGACGCGGC 158 BCEP2-DAS --------- GTTCGGCGG--------- -CGAAGCGAAGAAGTACGACGAAATCGACGCGGC 42 BPSE-1710b GTCGGCGAAGTTCGGCGG--------- -CGAAGCGAAGAAGTACGACGAAATCGACGCGGC 158 55 SMAL-DAS GCCGAGCGC-TTCGGTGG--------- -CGAGTTCAAGGACTACTCCTCGATCGACGCCGC 63 PAER-PAO1 CTCCGATACCTGGGGTGG---------TTCCGCTCGTGCTTTCGATCAGATCGACAACGC 158 KPNE-DAS --------- CTACGGTGG --------- -TTCCGCTCGCGCATTCGACCAGATCGATAACGC 42 MAVI-K1O GCACGACAAGTACCCGGACCTGA---ACGAGTCCCGCGCGTTCGACCAGATCGACAACGC 164 MAVI-paratub GCACGACAAGTACCCGGACCTGA ---ACGAGTCCCGCGCGTTCGACCAGATCGACAACGC 164 60 MAISpig-DAS GCACGACAAGTACCCGGACCTGA ---ACGAGTCCCGCGCGTTCGACCAGATCGACAACGC 59 MKAN-DAS GCATGACAAGTTCCCGGACCTGA---ACGAGTCGAAGGCGTTCGACCAGATCGACAACGC 65 MTUB-H37RV GCACGACAAATTCCCCGATCTGA - -ACGAGACGAAGGCATTCGACCAGATCGACAACGC 164 MTUB-CDC1551 GCACGACAAATTCCCCGATCTGA---ACGAGACGAAGGCATTCGACCAGATCGACAACGC 164 MAVI-DAS ------------------------------------------------------- AACGC 5 65 NCTC13129 GGCAGACGCTTACCCAGAGCTGA---ACGAAGCTTTCGCTTTCGATGCCATCGATAAGGC 164 NMEN-MC58 GGCTAAAAAATTCGGCGG--------- -TGCTGCAAAAGCTTACGACCAAATCGACAACGC 158 NMEN-Z2491 GGCTAAAAAATTCGGCGG---------TGCTGCAAAAGCTTACGACCAAATCGACAACGC 158 NMEN-DAS ----------------------------------------------------------- 70 MPNE-HF2 ACCTGAAGAAAAAGCTAGAGGTATTACTATTAATACTGCTCACGTTGAATATGAAACAGA 218 MPNE-M129 TCCGGAAGAAAAAGCACGGGGAATTACGATTAACTCCGCTCACGTGGAGTACTCCTCTGA 218 LPNE-Paris GCCAGAAGAAAGAGAGCGTGGTATTACTATTTCTACAGCACACGTTGAGTACGAATCAGC 231 LPNE2-DAS GCCAGAAGAAAGAGAGCGTGGGATTACTATTTCTACAGCACATGTTGAATACGAATCAGC 101 WO 2007/012131 PCT/AU2006/001056 -24 LPNE-Philadelphial GCCAGAAGAAAGAGAGCGTGGGATTACTATTTCTACAGCACATGTTGAATACGAATCAGC 218 LPNE-Lens GCCAGAAGAAAGAGAGCGTGGTATTACTATATCTACAGCCCATGTTGAATACGAATCAGC 218 LLON-DAS ACCAGAAGAAAGAGAGCGAGGCATCACAATCTCAACAGCGCACGTTGAATACGAATCAGC 102 FNUC-DAS TCCAGAAGAAAAAGAAAGAGGAATTACTATTAATACAGCTCATATTGAATATGAAACAGC 96 5 CPNE-CWL029 TCCAGAAGAAAAGGCTCGTGGAATTACTATCAACGCTTCTCACGTTGAATACGAAACCCC 218 EFAE-DAS TCCAGAAGAAAAAGAACGTGGAATCACAATCAACACTTCTCATATCGAATATGAAACTGA 95 EFAE -V583 TCCAGAAGAAAAAGAACGTGGAATCACAATCAACACTTCTCATATCGAATATGAAACTGA 218 SAUR-Mu50 TCCAGAAGAAAAAGAACGTGGTATCACAATCAATACTTCTCACATTGAGTACCAAACTGA 218 SAUR-N315 TCCAGAAGAAAAAGAACGTGGTATCACAATCAATACTTCTCACATTGAGTACCAAACTGA 218 10 SAUR-MW2 TCCAGAAGAAAAAGAACGTGGTATCACAATCAATACTTCTCACATTGAGTACCAAACTGA 218 SAUR-MSSA476 TCCAGAAGAAAAAGAACGTGGTATCACAATCAATACTTCTCACATTGAGTACCAAACTGA 218 SAUR-MRSA252 TCCAGAAGAAAAAGAACGTGGTATCACAATCAATACTTCACACATTGAGTACCAAACTGA 218 SEPI-12228 TCCAGAAGAAAAAGAACGTGGTATTACAATCAATACTGCACATATCGAATACCAAACTGA 218 SEPI-RP62A TCCAGAAGAAAAAGAACGTGGTATTACAATCAATACTGCACATATCGAATACCAAACTGA 218 15 SMIT-DAS TCCAGAAGAACGCGAACGCGGTATCACTATCAACACTGCGCACGTTGAGTACGAAACTGA 86 SSAN-DAS TCCAGAAGAACGCGAACGCGGAATCACTATCAACACTGCGCACGTTGAGTATGAAACTGC 127 SMIT-NCTC12261 TCCAGAAGAACGCGAACGTGGTATCACAATCAACACTGCGCACGTTGAGTACGAAACTGA 227 SPNE-R6 TCCAGAAGAACGCGAACGCGGTATCACTATCAACACTGCGCACGTTGAGTACGAAACTGA 227 SPYO-M1GAS TCCAGAAGAACGCGAACGCGGAATCACTATCAACACTGCACACGTTGAGTACGAAACTGC 227 20 SMUT-DAS TCCTGAAGAACGCGAACGCGGTATCACTATCAATACTGCGCACGTTGAGTATGAAACTGA 127 SMUT-UA159 TCCTGAAGAACGCGAACGCGGTATCACTATCAATACTGCGCACGTTGAGTATGAAACTGA 227 HINF-RdKW20 GCCAGAAGAAAAAGCGCGTGGTATTACCATCAACACTTCACACGTTGAATACGATACACC 218 MCAT-DAS ACCTGAAGAAAAAGCACGTGGTATTACTATTAACACATCTCACATCGAGTATGACACAGA 69 BPER-TohamaI GCCGGAAGAGAAGGCGCGTGGGATCACGATCAACACCTCGCACGTTGAGTACGAGACGGA 218 25 BPAR-12822 GCCGGAAGAGAAGGCGCGTGGGATCACGATCAACACCTCGCACGTTGAGTACGAGACGGA 218 BCEP2-DAS GCCGGAAGAAAAGGCACGCGGCATCACGATCAACACCGCGCACATCGAGTACGAAACGGC 102 BPSE-1710b GCCGGAAGAAAAGGCGCGCGGCATCACGATCAACACCGCGCACATCGAGTACGAAACGGC 218 SMAL-DAS GCCGGAAGAAAAGGCTCGTGGTATCACGATCTCGACCGCGCACGTCGAATACGAATCCCC 123 PAER-PA01 GCCGGAAGAAAAGGCCCGCGGTATCACCATCAACACCTCGCACGTTGAATACGATTCCGC 218 30 KPNE -DAS GCCGGAAGAAAAAGCTCGTGGTATCACCATCAACACCTCTCACGTTGAATATGACACCCC 102 MAVI-Ki0 GCCCGAGGAGCGTCAGCGCGGTATCACCATCAACATCTCCCACGTGGAGTACCAGACCGA 224 MAVI-paratub GCCCGAGGAGCGTCAGCGCGGTATCACCATCAACATCTCCCACGTGGAGTACCAGACCGA 224 MAISpig-DAS TCCCGAGGAGCGTCAGCGCGGTATCACGATCAACATCTCCCACGTGGAGTACCAGACCGA 119 MKAN-DAS TCCTGAGGAGCGCCAGCGCGGTATCACGATCAACATCGCGCACGTGGAGTACCAGACCGA 125 35 MTUB-H37Rv CCCCGAGGAGCGTCAGCGCGGTATCACCATCAACATCGCGCACGTGGAGTACCAGACCGA 224 MTUB-CDC1551 CCCCGAGGAGCGTCAGCGCGGTATCACCATCAACATCGCGCACGTGGAGTACCAGACCGA 224 MAVI-DAS GCCTGAAGAGCGTCAGCGCGGTATCACCATCAACATCTCGCATGTTGAGTACCAGACCGA 65 CIDP-NCTC13129 ACCGGAAGAGAAAGAGCGTGGTATTACCATCAACATCTCCCACGTGGAGTACCAGACCGA 224 NMEN-MC58 ACCCGAAGAAAAAGCACGCGGTATTACCATTAACACCTCGCACGTGGAATACGAAACCGA 218 40 NMEN-Z2491 ACCCGAAGAAAAAGCACGCGGTATTACCATTAACACCTCGCACGTGGAATACGAAACCGA 218 NMEN-DAS -CCCGAAGAAAAAGCACGCGGTATTACCATTAACACCTCGCACGTGGAATACGAAACCGA 59 MPNE-HF2 AAACAGACACTATGCTCACGTAGACTGTCCAGGTCACGCTGACTACGTTAAGAACATGAT 278 MPNE-M129 CAAGCGTCACTATGCTCACGTTGACTGTCCAGGACACGCTGACTACATTAAGAACATGAT 278 45 LPNE-Paris GAGCAGACATTATGCGCACGTAGACTGCCCGGGGCATGCTGACTATGTTAAGAACATGAT 291 LPNE2-DAS GAGCAGACATTATGCGCACGTAGACTGCCCGGGGCATGCTGACTATGTTAAGAACATGAT 161 LPNE-Philadelphial GAGCAGACATTATGCACACGTAGACTGCCCGGGACATGCTGACTATGTTAAGAACATGAT 278 LPNE-Lens GAGCAGACATTATGCACACGTAGACTGCCCGGGACATGCTGACTATGTTAAGAACATGAT 278 LLON-DAS GAACAGACACTATGCGCATGTTGATTGCCCAGGACATGCTGACTATGTGAAGAACATGAT 162 50 FNUC-DAS AAATAGACACTATGCTCACGTTGACTGTCCAGGGCATGCTGACTATGTTAAAAATATGAT 156 CPNE-CWL029 AAATCGTCACTACGCTCACGTAGACTGCCCTGGTCACGCTGACTATGTTAAAAATATGAT 278 EFAE-DAS AACTCGTCACTATGCACACGTTGACTGCCCAGGACACGCGGACTACGTTAAAAACATGAT 155 EFAE-V583 AACTCGTCACTATGCACACGTTGACTGCCCAGGACATGCGGACTACGTTAAAAACATGAT 278 SAUR-Mu50 CAAACGTCACTACGCTCACGTTGACTGCCCAGGACACGCTGACTACGTTAAAAACATGAT 278 55 SAUR-N315 CAAACGTCACTACGCTCACGTTGACTGCCCAGGACACGCTGACTACGTTAAAAACATGAT 278 SAUR-MW2 CAAACGTCACTACGCTCACGTTGACTGCCCAGGACACGCTGACTACGTTAAAAACATGAT 278 SAUR-MSSA476 CAAACGTCACTACGCTCACGTTGACTGCCCAGGACACGCTGACTACGTTAAAAACATGAT 278 SAUR-MRSA252 CAAACGTCACTACGCTCACGTTGACTGCCCAGGACACGCTGACTATGTTAAAAACATGAT 278 SEPI-12228 CAAACGTCACTATGCTCACGTTGACTGCCCAGGACACGCTGACTATGTTAAAAACATGAT 278 60 SEPI-RP62A CAAACGTCACTATGCTCACGTTGACTGCCCAGGACACGCTGACTATGTTAAAAACATGAT 278 SMIT-DAS AAAACGTCACTACGCTCACATCGACGCTCCAGGACACGCGGACTACGTTAAAAACATGAT 146 SSAN-DAS TAAGCGTCACTACGCTCACATCGACGCTCCAGGACACGCGGACTACGTTAAAAACATGAT 187 SMIT-NCTC12261 AAAACGTCACTACGCTCACATCGACGCTCCAGGACACGCGGACTATGTTAAAAACATGAT 287 SPNE-R6 AAAACGTCACTACGCTCACATCGACGCTCCAGGACACGCGGACTACGTTAAAAACATGAT 287 65 SPYO-MIGAS AACTCGTCACTATGCGCACATCGACGCTCCAGGACACGCGGACTACGTTAAAAACATGAT 287 SMUT-DAS AAAACGTCACTATGCTCACATTGACGCTCCAGGACACGCGGACTATGTTAAAAACATGAT 187 SMUT-UA159 AAAACGTCACTATGCTCACATTGATGCTCCAGGACACGCGGACTATGTTAAAAACATGAT 287 HINF-RdKW20 GACTCGCCACTACGCACACGTAGACTGTCCGGGACACGCCGACTATGTTAAAAATATGAT 278 MCAT-DAS AGCTCGTCACTACGCACATGTAGACTGCCCAGGCCACGCTGACTATGTTAAAAACATGAT 129 70 BPER-Tohamal GACGCGTCACTACGCGCACGTTGATTGCCCGGGTCACGCTGACTACGTGAAGAACATGAT 278 BPAR-12822 GACGCGTCACTACGCGCACGTTGATTGCCCGGGTCACGCTGACTACGTGAAGAACATGAT 278 BCEP2-DAS GAACCGCCACTACGCGCACGTCGACTGCCCGGGCCACGCCGACTACGTGAAGAACATGAT 162 BPSE-1710b GAACCGCCACTACGCACACGTGGACTGCCCGGGCCACGCCGACTACGTGAAGAACATGAT 278 WO 2007/012131 PCT/AU2006/001056 -25 SMAL-DAS GATCCGTCACTACGCCCACGTTGACTGCCCGGGCCACGCTGACTACGTCAAGAACATGAT 183 PAER-PA01 TGTTCGTCACTACGCCCACGTTGACTGCCCCGGTCACGCCGACTACGTGAAGAACATGAT 278 KPNE-DAS GACTCGCCACTACGCGCACGTAGACTGCCCGGGCCACGCCGACTATGTTAAAAACATGAT 162 MAVI-K10 CAAGCGGCACTACGCTCACGTCGACGCCCCGGGTCACGCCGACTACATCAAGAACATGAT 284 5 MAVI-paratub CAAGCGGCACTACGCTCACGTCGACGCCCCGGGTCACGCCGACTACATCAAGAACATGAT 284 MAISpig-DAS CAAGCGGCACTATGCCCACGTCGACGCCCCGGGTCACGCCGACTACATCAAGAACATGAT 179 MKAN-DAS GAAGCGGCACTATGCACACGTCGACGCGCCGGGCCACGCCGACTACATCAAGAACATGAT 185 MTUB-H37RV CAAGCGGCACTACGCACACGTCGACGCCCCTGGCCACGCCGACTACATCAAGAACATGAT 284 MTUB-CDC1551 CAAGCGGCACTACGCACACGTCGACGCCCCTGGCCACGCCGACTACATCAAGAACATGAT 284 10 MAVI-DAS GAAGCGCCACTACGCACACGTGGACGCCCCCGGCCACGCGGACTACATCAAGAACATGAT 125 CIDP-NCTC13129 GAAGCGCCACTACGCACACGTTGACGCTCCAGGTCACGCTGACTACATCAAGAACATGAT 284 NMEN-MC58 AACCCGCCACTACGCACACGTAGACTGCCCGGGGCACGCCGACTACGTTAAAAACATGAT 278 NMEN-Z2491 AACCCGCCACTACGCACACGTAGACTGTCCGGGGCACGCCGACTACGTTAAAAACATGAT 278 15 NMEN-DAS AACCCGCCACTACGCACACGTAGACTGCCCGGGGCACGCCGACTACGTTAAAAACATGAT 119 MPNE-HF2 TACTGGTGCTGCTCAAATGGATGGTGCAATCTTAGTAGTTGCTGCATCTGATGGACCAAT 338 MPNE-M129 TACTGGTGCTGCACAAATGGATGGTGCCATTCTAGTAGTTTCAGCAACTGACAGTGTTAT 338 LPNE-Paris TACTGGTGCTGCGCAAATGGACGGAGCGATACTGGTTGTATCAGCAGCTGATGGTCCTAT 351 LPNE2-DAS TACTGGTGCTGCGCAAATGGACGGAGCGATACTGGTTGTATCAGCAGCTGATGGTCCTAT 221 20 LPNE-Philadelphial TACTGGTGCTGCGCAAATGGACGGAGCGATACTGGTTGTATCAGCAGCTGATGGTCCTAT 338 LPNE-Lens TACTGGTGCTGCGCAAATGGACGGAGCGATACTGGTTGTATCAGCAGCTGATGGTCCTAT 338 LLON-DAS TACAGGTGCTGCACAAATGGACGGAGCGATACTTGTAGTATCTGCAGCAGATGGTCCTAT 222 FNUC-DAS AACTGGTGCTGCACAAATGGATGGAGCTATACTTGTTGTATCAGCTGCTGATGGTCCTAT 216 CPNE-CWL029 TACAGGCGCCGCTCAAATGGACGGAGCTATCCTAGTCGTTTCAGCTACAGACGGAGCTAT 338 25 EFAE-DAS CACTGGTGCTGCTCAAATGGACGGAGCTATCTTAGTAGTTTCTGCTGCTGATGGTCCTAT 215 EFAE -VS83 CACTGGTGCTGCTCAAATGGACGGAGCTATCTTAGTAGTTTCTGCTGCTGATGGTCCTAT 338 SAUIR-Mu50 CACTGGTGCTGCTCAAATGGACGGCGGTATCTTAGTAGTATCTGCTGCTGACGGTCCAAT 338 SAUR-N315 CACTGGTGCTGCTCAAATGGACGGCGGTATCTTAGTAGTATCTGCTGCTGACGGTCCAAT 338 SAUR-MW2 CACTGGTGCTGCTCAAATGGACGGCGGTATCTTAGTAGTATCTGCTGCTGACGGTCCAAT 338 30 SAUR-MSSA476 CACTGGTGCTGCTCAAATGGACGGCGGTATCTTAGTAGTATCTGCTGCTGACGGTCCAAT 338 SAUR-MRSA252 CACTGGTGCTGCTCAAATGGACGGTGGTATCTTAGTAGTATCTGCTGCTGACGGTCCAAT 338 SEPI-12228 CACTGGTGCAGCTCAAATGGACGGCGGTATCTTAGTTGTATCTGCTGCTGACGGTCCAAT 338 SEPI-RP62A CACTGGTGCAGCTCAAATGGACGGCGGTATCTTAGTTGTATCTGCTGCTGACGGTCCAAT 338 SMIT-DAS CACTGGTGCCGCTCAAATGGACGGAGCTATCCTTGTAGTAGCTTCAACTGACGGACCAAT 206 35 SSAN-DAS CACTGGTGCCGCTCAAATGGACGGAGCTATCCTTGTAGTAGCTTCAACTGACGGACCAAT 247 SMIT-NCTC12261 CACTGGTGCCGCTCAAATGGACGGAGCTATCCTTGTAGTAGCTTCAACTGACGGACCAAT 347 SPNE-R6 CACTGGTGCTGCTCAAATGGACGGAGCTATCCTTGTAGTAGCTTCAACTGACGGACCAAT .347 SPYO-M1GAS CACTGGTGCCGCTCAAATGGACGGAGCTATCCTTGTAGTTGCTTCAACTGATGGACCAAT 347 SMUT-DAS TACTGGTGCTGCCCAAATGGATGGTGCTATCCTTGTAGTAGCTTCAACTGATGGTCCAAT 247 40 SMUT-UA159 CACTGGTGCTGCCCAAATGGATGGTGCTATCCTTGTAGTAGCTTCAACTGATGGACCAAT 347 HINF-RdKW20 TACTGGTGCGGCACAAATGGATGGTGCTATTTTAGTAGTAGCAGCAACAGATGGTCCTAT 338 MCAT-DAS CACAGGTGCTGCACAGATGGACGGCGCAATCTTGGTTGTTTCTGCAACTGACGGCCCAAT 189 BPER-TohamaI CACGGGTGCTGCGCAGATGGACGGCGCGATCCTGGTGGTGTCGGCCGCAGACGGCCCGAT 338 BPAR-12822 CACGGGTGCTGCGCAGATGGACGGCGCGATCCTGGTGGTGTCGGCCGCAGACGGCCCGAT 338 45 BCEP2-DAS CACGGGTGCAGCGCAGATGGACGGCGCAATCCTGGTGTGCTCGGCCGCAGACGGCCCGAT 222 BPSE-1710b CACGGGCGCGGCGCAGATGGACGGCGCGATCCTGGTGTGCTCGGCCGCTGACGGCCCCAT 338 SMAL-DAS CACCGGTGCCGCCCAGATGGACGGCGCGATCCTGGTGTGCTCGGCCGCTGACGGCCCGAT 243 PAER-PA01 CACCGGTGCTGCCCAGATGGACGGCGCGATCCTGGTTTGCTCGGCTGCCGACGGCCCCAT 338 KPNE-DAS CACCGGTGCTGCGCAGATGGACGGCGCGATCCTGGTTGTTGCTGCGACTGACGGCCCGAT 222 50 MAVI-Kl0 CACCGGCGCCGCCCAGATGGACGGCGCGATCCTGGTGGTCGCCGCCACCGACGGCCCGAT 344 MAVI-paratub CACCGGCGCCGCCCAGATGGACGGCGCGATCCTGGTGGTCGCCGCCACCGACGGCCCGAT 344 MAISpig-DAS CACCGGTGCGGCCCAGATGGACGGCGCGATCCTGGTGGTTGCCGCCACCGACGGCCCGAT 239 MKAN-DAS CACCGGCGCCGCCCAGATGGACGGCGCGATCCTGGTGGTCGCCGCCACGGACGGCCCGAT 245 MTUB-H37Rv CACCGGCGCCGCGCAGATGGACGGTGCGATCCTGGTGGTCGCCGCCACCGACGGCCCGAT 344 55 MTUB-CDC1551 CACCGGCGCCGCGCAGATGGACGGTGCGATCCTGGTGGTCGCCGCCACCGACGGCCCGAT 344 MAVI-DAS CACCGGTGCCGCCCAGATGGACGGCGCGATCCTGGTGGTCGCCGCGACCGACGGCCCGAT 185 NCTC13129 CACCGGTGCTGCTCAGATGGACGGCGCAATCCTCGTTGTTGCTGCCACCGACGGCCCAAT 344 NMEN-MC58 TACCGGCGCCGCACAAATGGACGGTGCAATCCTGGTATGTTCCGCAGCCGACGGCCCTAT 338 NMEN-Z2491 TACCGGCGCAGCACAAATGGACGGTGCAATCCTGGTATGTTCCGCAGCCGACGGCCCTAT 338 60 NMEN-DAS TACCGGTGCCGCACAAATGGACGGTGCAATCCTGGTATGTTCCGCAGCCGACGGCCCTAT 179 MPNE-HF2 GCCACAAACAAGAGAACACATCTTATTAGCTAGACAAGTTGGTGTTCCTAAAATGGTAGT 398 MPNE-M129 GCCCCAAACCCGTGAACACATTTTGTTGGCCCGCCAAGTGGGTGTGCCACGCATGGTAGT 398 LPNE-Paris GCCACAAACGAGGGAACACATTCTATTGTCTCGCCAGGTAGGTGTTCCATATATTGTTGT 411 65 LPNE2-DAS GCCACAAACGAGGGAACACATTCTATTGTCTCGCCAGGTAGGTGTTCCATATATTGTTGT 281 LPNE-Philadelphial GCCACAAACGAGGGAACACATTCTATTGTCTCGCCAGGTAGGTGTTCCATATATTGTTGT 398 LPNE-Lens GCCACAAACGAGGGAACACATTCTATTGTCTCGCCAGGTAGGTGTTCCATATATTGTTGT 398 LLON-DAS GCCTCAAACTAGAGAACATATTCTATTGTCACGACAAGTAGGGGTGCCCTACATAGTAGT 282 FNUC-DAS GCCTCAAACAAGAGAACATATCTTACTTTCTAGACAAGTTGGAGTACCATATATTATTGT 276 70 CPNE-CWL029 GCCACAAACTAAAGAACATATCTTGCTAGCTCGCCAGGTTGGAGTTCCTTATATCGTTGT 398 EFAE-DAS GCCTCAAACACGTGAACATATCTTATTATCACGTAACGTTGGTGTACCATACATCGTTGT 275 EIAE -V583 GCCTCAAACACGTGAACATATCTTATTATCACGTAACGTTGGTGTACCATACATCGTTGT 398 SAUR-Mu50 GCCACAAACTCGTGAACACATTCTTTTATCACGTAACGTTGGTGTACCAGCATTAGTAGT 398 WO 2007/012131 PCT/AU2006/001056 - 26 SAUR-N315 GCCACAAACTCGTGAACACATTCTTTTATCACGTAACGTTGGTGTACCAGCATTAGTAGT 398 SAUR-MW2 GCCACAAACTCGTGAACACATTCTTTTATCACGTAACGTTGGTGTACCAGCATTAGTAGT 398 SAUR-MSSA476 GCCACAAACTCGTGAACACATTCTTTTATCACGTAACGTTGGTGTACCAGCATTAGTAGT 398 SAUR-MRSA252 GCCACAAACTCGTGAACACATTCTTTTATCACGTAACGTTGGTGTACCAGCATTAGTAGT 398 5 SEPI-12228 GCCACAAACTCGTGAACACATCTTATTATCACGTAACGTTGGTGTACCAGCATTAGTTGT 398 SEPI-RP62A GCCACAAACTCGTGAACACATCTTATTATCACGTAACGTTGGTGTACCAGCATTAGTTGT 398 SMIT-DAS GCCACAAACTCGTGAGCACATCCTTCTTTCACGTCAGGTTGGTGTTAAACACTTGATCGT 266 SSAN-DAS GCCACAAACTCGTGAGCACATCTTGCTTTCACGTCAGGTTGGTGTTAAACACTTGATCGT 307 SMIT-NCTC12261 GCCACAAACTCGTGAGCACATCCTTCTTTCACGTCAGGTTGGTGTTAAACACCTTATCGT 407 10 SPNE-R6 GCCACAAACTCGTGAGCACATCCTTCTTTCACGTCAGGTTGGTGTTAAACACCTTATCGT 407 SPYO-M1GAS GCCACAAACTCGTGAGCACATCCTTCTTTCACGTCAGGTTGGTGTTAAACACCTTATCGT 407 SMUT-DAS GCCACAAACTCGTGAACACATTCTTCTTTCACGTCAAGTTGGTGTTAAATACCTTATTGT 307 SMUT-UA159 GCCACAAACTCGTGAACACATTCTTCTTTCACGTCAAGTTGGTGTTAAATACCTCATTGT 407 HINF-RdKW20 GCCACAAACTCGTGAACACATCTTATTAGGTCGCCAAGTAGGTGTTCCATACATCATCGT 398 15 MCAT-DAS GCCACAAACTCGTGAGCACATCCTACTGTCTCGTCAGGTTGGTGTACCATATATCATGGT 249 BPER-TohamaI GCCGCAGACGCGCGAGCACATTTTGCTGTCGCGCCAGGTTGGCGTGCCGTACATCATCGT 398 BPAR-12822 GCCGCAGACGCGCGAGCACATTTTGCTGTCGCGCCAGGTTGGCGTGCCGTACATCATCGT 398 BCEP2-DAS GCCGCAAACGCGTGAGCACATCCTGCTGGCGCGTCAGGTTGGCGTTCCGTACATCATCGT 282 BPSE-1710b GCCGCAAACGCGTGAGCACATCCTGCTGGCGCGTCAGGTCGGTGTGCCGTACATCATCGT 398 20 SMAL-DAS GCCGCAGACCCGTGAGCACATCCTGCTGTCGCGCCAGGTCGGCGTGCCGTACATCGTCGT 303 PAER-PA01 GCCGCAGACCCGCGAGCACATCCTGCTGTCCCGCCAGGTAGGCGTTCCCTACATCGTCGT 398 KPNE-DAS GCCGCAGACTCGTGAGCACATCCTGCTGGGTCGTCAGGTAGGCGTTCCGTACATCATCGT 282 MAVI-K10 GCCGCAGACCCGCGAGCACGTGCTGCTGGCCCGTCAGGTCGGTGTGCCCTACATCCTGGT 404 MAVI-paratub GCCGCAGACCCGCGAGCACGTGCTGCTGGCCCGTCAGGTCGGTGTGCCCTACATCCTGGT 404 25 MAISpig-DAS GCCGCAGACCCGTGAGCACGTGCTGCTCGCGCGTCAGGTCGGGGTGCCCTACATCCTGGT 299 MKAN-DAS GCCGCAGACCCGTGAGCACGTGCTGCTCGCACGTCAGGTGGGTGTGCCCTACATCCTGGT 305 MTUB-H37Rv GCCCCAGACCCGCGAGCACGTTCTGCTGGCGCGTCAAGTGGGTGTGCCCTACATCCTGGT 404 MTUB-CDC1551 GCCCCAGACCCGCGAGCACGTTCTGCTGGCGCGTCAAGTGGGTGTGCCCTACATCCTGGT 404 MAVI-DAS GCCGCAGACCCGCGAGCACGTGCTGCTCGGCCGTCAGGTGGGTGTGCCCTACATCCTCGT 245 30 NCTC13129 GCCTCAGACCCGTGAGCACGTTCTGCTCGCTCGCCAGGTCGGCGTTCCTTACATCCTCGT 404 NMEN-MC58 GCCGCAAACCCGCGAACACATCCTGCTGGCCCGCCAAGTAGGCGTACCTTACATCATCGT 398 NMEN-Z2491 GCCGCAAACCCGCGAACACATCCTGCTGGCCCGTCAAGTAGGCGTACCTTACATCATCGT 398 NMEN-DAS GCCGCAAACCCGCGAACACATCCTGCTGGCCCGTCAAGTAGGCGTACCTTACATCATCGT 239 35 MPNE-HF2 TTTCTTAAACAAATGTGATATGGTA------TCTGATGCTGAAATGCAAGACCTAGTAGA 452 MPNE-M129 GTTCCTAAACAAGTGTGACATTGCA ----- ACTGATGAAGAAGTGCAAGAGTTAGTAGC 452 LPNE-Paris GTTCATGAACAAAGCGGATATGGTT ----- GATGACCCTGAGTTATTAGAGTTAGTGGA 465 LPNE2-DAS GTTCATGAACAAAGCGGATATGGTT------GATGACCCTGAGTTATTAGAGTTAGTGGA 335 LPNE-Philadelphial GTTCATGAACAAAGCGGATATGGTT------GATGACCCTGAGTTATTAGAGTTAGTGGA 452 40 LPNE- Lens GTTCATGAACAAAGCGGATATGGTT ----- GATGACCCTGAGTTATTAGAGTTAGTGGA 452 LLON-DAS GTTTATGAATAAAGCGGACATGGTT------GATGATCCAGAGCTCTTAGAGCTTGTAGA 336 FNUC-DAS TTATTTAAATAAATCAGATATGGTT------GATGATGAAGAATTACTAGAATTGGTAGA 330 CPNE-CWL029 TTTCTTGAATAAAGTAGATATGATCTCTCAAGAAGATGCTGAACTTATTGACCTTGTTGA 458 EFAE-DAS ATTCTTAAACAAAATGGATATGGTT------GATGACGAAGAATTATTAGAATTAGTAGA 329 45 EFAE-V583 ATTCTTAAACAAAATGGATATGGTT------GATGACGAAGAATTATTAGAATTAGTAGA 452 SAUR-Mu50 ATTCTTAAACAAAGTTGACATGGTT------GACGATGAAGAATTATTAGAATTAGTAGA 452 SAUR-N315 ATTCTTAAACAAAGTTGACATGGTT ------ GACGATGAAGAATTATTAGAATTAGTAGA 452 SAUR-MW2 ATTCTTAAACAAAGTTGACATGGTT------GACGATGAAGAATTATTAGAATTAGTAGA 452 SAUR-MSSA476 ATTCTTAAACAAAGTTGACATGGTT ------ GACGATGAAGAATTATTAGAATTAGTAGA 452 50 SAUR-MRSA252 ATTCTTAAACAAAGTTGACATGGTT------GACGATGAAGAATTATTAGAATTAGTAGA 452 SEPI-12228 ATTCTTAAACAAAGTTGACATGGTA------GACGACGAAGAATTATTAGAATTAGTTGA 452 SEPI -RP62A ATTCTTAAACAAAGTTGACATGGTA ----- GACGACGAAGAATTATTAGAATTAGTTGA 452 SMIT-DAS CTTCATGAACAAAGTTGACTTGGTT------GACGATGAAGAATTGCTTGAATTGGTTGA 320 SSAN-DAS CTTCATGAACAAAGTTGACTTGGTT ------ GACGATGAAGAATTGCTTGAATTGGTTGA 361 55 SMIT-NCTC12261 CTTCATGAACAAAGTTGACTTGGTT ------ GACGACGAAGAATTGCTTGAATTGGTTGA 461 SPNE-R6 CTTCATGAACAAAGTTGACTTGGTT------GACGACGAAGAATTGCTTGAATTGGTTGA 461 SPYO-M1GAS GTTCATGAACAAAGTTGACCTTGTT ------ GATGACGAAGAGTTGCTTGAATTAGTTGA 461 SMUT-DAS CTTCATGAATAAGGTTGATTTGGTT------GATGATGAAGAACTGCTTGAATTGGTTGA 361 SMUT-UA159 CTTCATGAATAAAGTTGATTTGGTT------GACGATGAAGAATTGCTTGAATTGGTTGA 461 60 HINF-RdKW20 ATTCTTAAACAAATGCGACATGGTA------GATGACGAAGAGTTATTAGAATTAGTCGA 452 MCAT-DAS ATTCATGAACAAGTGCGACATGGTA------GATGATGAAGAGCTACTAGAATTGGTTGA 303 BPER-Tohamal GTTCCTGAACAAGGCGGACATGGTT------GATGACGCGGAGCTGCTCGAGCTGGTGGA 452 BPAR-12822 GTTCCTGAACAAGGCGGACATGGTT------GATGACGCGGAGCTGCTCGAGCTGGTGGA 452 BCEP2-DAS GTTCCTGAACAAGTGCGACATGGTG------GACGACGCTGAACTGCTCGAGCTGGTCGA 336 65 BPSE-1710b GTTCCTGAACAAGTGCGATATGGTG------GACGACGCGGAGCTGCTCGAGCTGGTCGA 452 SMAL-DAS GTTCCTGAACAAGGCCGACATGGTC ------ GACGACGCCGAGCTGCTCGAGCTGGTCGA 357 PAER-PAO1 GTTCCTGAACAAGGCCGACATGGTC------GACGACGCCGAGCTGCTGGAACTGGTCGA 452 KPNE-DAS GTTCCTGAACAAATGCGACATGGTT------GATGACGAAGAGCTGCTGGAACTGGTTGA 336 MAVI-K10 CGCGCTGAACAAGGCCGACATGGTC ------ GACGACGAGGAGCTGCTCGAGCTCGTCGA 458 70 MAVI-paratub CGCGCTGAACAAGGCCGACATGGTC ------ GACGACGAGGAGCTGCTCGAGCTCGTCGA 458 MAISpig-DAS CGCCCTCAACAAGGCCGACATGGTC ------ GACGACGAGGAGCTCCTCGAGCTCGTCGA 353 MKAN-DAS CGCGCTGAACAAGGCCGACGCCGTC ------ GACGACGAGGAGTTGCTCGAACTCGTCGA 359 MTUB-H3 7Rv AGCGCTGAACAAGGCCGACGCAGTG ------ GACGACGAGGAGCTGCTCGAACTCGTCGA 458 WO 2007/012131 PCT/AU2006/001056 - 27 MTUB-CDC1551 AGCGCTGAACAAGGCCGACGCAGTG ------ GACGACGAGGAGCTGCTCGAACTCGTCGA 458 MAVI-DAS GGCGCTGAACAAGTCGGACATGGTC ------ GACGACGAGGAGCTCCTCGAGCTCGTCGA 299 NCTC13129 TGCTCTGAACAAGTGCGACATGGTT ------ GATGATGAGGAAATCATCGAGCTCGTCGA 458 NMEN-MC58 GTTCATGAACAAATGCGACATGGTC------GACGATGCCGAGCTGTTGGAACTGGTTGA 452 5 NMEN- Z24 91 GTTCATGAACAAATGCGACATGGTC ----- GACGATGCCGAGCTGTTGGAACTGGTTGA 452 NMEN-DAS GTTCATGAACAAATGCGACATGGTC------GACGATGCCGAGCTGTTGGAACTGGTTGA 293 MPNE-HF2 AATGGAAGTTAGAGAATTACTTTCTTCTTATGGTTTTGATGGAGATAACACTCCAGTTAT 512 MPNE-M129 AGAAGAGGTACGTGACTTATTAACTTCTTACGGCTTTGATGGCAAGAACACCCCTATTAT 512 10 LPNE-Paris AATGGAAGTGCGAGATTTATTAAGCAGTTACGATTTCCCAGGGGATGACATACCTATTGT 525 LPNE2-DAS AATGGAAGTGCGAGATTTATTAAGCAGTTACGATTTCCCAGGGGATGACATACCCATTGT 395 LPNE-Philadelphial AATGGAAGTGCGAGATTTATTAAGCAGTTACGATTTCCCAGGGGATGACATACCTATTGT 512 LPNE-Lens AATGGAAGTGCGAGATTTATTAAGCAGTTACGATTTCCCAGGGGATGATATACCTATTAT 512 LLON-DAS AATGGAAGTCCGTGATTTGTTGAGCAGTTATGATTTTCCTGGTGATGATATTCCAATTGT 396 15 FNUC-DAS AATGGAAGTTAGAGAATTATTAACTGAATATGGATTCCCAGGAGATGACATCCCTGTAAT 390 CPNE-CWL029 GATGGAACTTAGTGAGCTTCTTGAAGAAAAAGGCT--ACAAAGGATG----CCCTATTAT 512 EFAE-DAS AATGGAAGTTCGTGACTTATTATCAGAATACGATTTCCCAGGCGATGATGTTCCAGTTAT 389 EFAE-V583 AATGGAAGTTCGTGACTTATTATCAGAATACGATTTCCCAGGCGATGATGTTCCAGTTAT 512 SAUR-MuS0 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 20 SAUR-N315 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 SAUR-MW2 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 SAUR-MSSA476 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 SAUR-MRSA252 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 SEPI-12228 AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 25 SEPI-RP62A AATGGAAGTTCGTGACTTATTAAGCGAATATGACTTCCCAGGTGACGATGTACCTGTAAT 512 SMIT-DAS AATGGAAATCCGTGACCTTCTTTCAGAATACGATTTCCCAGGTGATGACCTTCCAGTTAT 380 SSAN-DAS AATGGAAATCCGTGACCTCTTGTCAGAATACGACTTCCCAGGTGACGATCTTCCAGTTAT 421 SMIT-NCTC12261 AATGGAAATCCGTGACCTATTGTCAGAATACGACTTCCCAGGTGACGATCTTCCAGTTAT 521 SPNE-R6 AATGGAAATCCGTGACCTATTGTCAGAATACGACTTCCCAGGTGACGATCTTCCAGTTAT 521 30 SPYO-M1GAS GATGGAAATTCGTGACCTTCTTTCAGAATACGATTTCCCAGGTGATGACCTTCCAGTTAT 521 SMUT-DAS AATGGAAATCCGTGATCTTCTTTCAGAATATGATTTCCCAGGTGATGATATTCCAGTTAT 421 SMUT-UA159 AATGGAAATCCGTGATCTTCTTTCAGAATATGATTTCCCAGGTGATGATATTCCAGTTAT 521 HINF-RdKW20 AATGGAAGTTCGTGAACTTCTATCTCAATATGACTTCCCAGGTGACGATACACCAATCGT 512 MCAT-DAS AATGGAAGTTCGTGAACTTCTATCTGACTATGACTTCCCAGGTGATGACACCCCAATCAT 363 35 BPER-TohamaI GATGGAAGTCCGCGAACTGCTGAGCAAGTACGATTTCCCGGGCGATGACACGCCGATCGT 512 BPAR-12822 GATGGAAGTCCGCGAACTGCTGAGCAAGTACGATTTCCCGGGCGATGACACGCCGATCGT 512 BCEP2-DAS GATGGAAGTTCGCGAACTGCTGTCGAAGTACGACTTCCCGGGCGACGACACGCCGATCAT 396 BPSE-1710b AATGGAAGTGCGCGAACTGCTGTCGAAGTACGACTTCCCGGGCGACGACACGCCGATCAT 512 SMAL-DAS GATGGAAGTGCGCGAACTGCTGAGCAAGTACGAGTTCCCGGGCGACGACACCCCGATCAT 417 40 PAER-PA01 GATGGAAGTTCGCGATCTGCTGAACACCTACGACTTCCCGGGCGACGACACTCCGATCAT 512 KPNE-DAS GATGGAAGTTCGTGAACTGCTGTCTCAGTACGATTTCCCGGGCGACGACACCCCGATCGT 396 MAVI-KlO GATGGAGGTCCGCGAGCTGCTGGCCGCCCAGGAGTTC- - -GACGAGGACGCCCCGGTGGT 515 MAVI-paratub GATGGAGGTCCGCGAGCTGCTGGCCGCCCAGGAGTTC--- GACGAGGACGCCCCGGTGGT 515 MAISpig-DAS GATGGAGGTCCGCGAACTGCTGGCCGCCCAGGAGTTC---GACGAGGACGCCCCGGTGGT 410 45 MKAN-DAS GATGGAGGTCCGCGAGCTGCTGGCCGCCCAGGAGTTC--- GACGAGGACGCCCCGGTGGT 416 MTUB-H3 7Rv GATGGAGGTCCGCGAGCTGCTGGCTGCCCAGGAATTC - -- GACGAGGACGCCCCGGTTGT 515 MTUB-CDC1551 GATGGAGGTCCGCGAGCTGCTGGCTGCCCAGGAATTC--- GACGAGGACGCCCCGGTTGT 515 MAVI-DAS GATGGAGGTCCGCGAACTGCTGGCCGCCCAGGAGTTC--- GACGAGGACGCCCCGGTCAT 356 NCTC13129 GATGGAGATCCGTGAGCTGCTCGCTGAGCAGGATTAC--- GACGAAGAGGCTCCAATCAT 515 50 NMEN-MC58 AATGGAAATCCGCGACCTGCTGTCCAGCTACGACTTCCCCGGCGATGACTGCCCGATTGT 512 NMEN-Z2491 AATGGAAATCCGCGACCTGCTGTCCAGCTACGACTTCCCCGGCGACGACTGCCCGATCGT 512 NMEN-DAS AATGGAAATCCGCGACCTGCTGTCCAGCTACGACTTCCCCGGCGACGACTGCCCGATTGT 353 MPNE-HF2 TAGAGGTTCAGCTTTAAAAGCATTAGAAGGT--- GAT ---- GCTACTTGAGAAGCTAAA- 564 55 MPNE-M129 TTATGGTTCTGCACTTAAAGCGCTTGAAGGT-- -GAT--- -CCTAAGTGGGAAGCTAAG- 564 LPNE- Paris TGTTGGTTCAGCTTTGAAAGCATTGGAAGGT- - -GAAGACAGTGATATAGGCGTTAAGGC 582 LPNE2-DAS TGTTGGTTCAGCTTTGAAAGCATTGGAAGGT---GAAGACAGTGATATAGGCGTTAAGGC 452 LPNE-Philadelphial TGTTGGTTCAGCTTTGAAAGCATTGGAAGGT- -- GAAGACAGTGATATAGGCGTTAAGGC 569 LPNE-Lens TGTTGGTTCAGCTTTGAAAGCATTGGAAGGT--- GAAGACAGTGATATAGGTGTTAAGGC 569 60 LLON-DAS TGTTGGATCTGCATTGAAAGCATTAGAAGGT--- GATACCAGTGATATTGGGGTGCCAGC 453 FNUC-DAS TAGAGGTTCATCATTAGGAGCTTTAAATGGT - -- A- - - -AGAAAAATGGATAGAAAAG- 442 CPNE-CWL029 CCGTGGTTCTGCTTTGAAAGCTCTTGAAGGT--- GATGCAAATTATATCGA--- AAAAG- 565 EFAE-DAS CGCAGGTTCTGCTTTGAAAGCTTTAGAAGGC--- GAC ---- GAGTCTTATGAAGAAAAA- 441 EFAE-VS83 CGCAGGTTCTGCTTTGAAAGCTTTAGAAGGC--- GAC ---- GAGTCTTATGAAGAAAAA- 564 65 SATJR-Mu5O CGCTGGTTCAGCATTAAAAGCTTTAGAAGGC---GAT----GCTCAATAcGAAGAAAAA- 564 SAUR-N315 CGCTGGTTCAGCATTAAAAGCTTTAGAAGGC -- -GAT --- -GCTCAATACGAAGAAAAA- 564 SAUR-MW2 CGCTGGTTCAGCATTAAAAGCTTTAGAAGGC--- GAT ---- GCTCAATACGAAGAAAAA- 564 SAUR-MSSA476 CGCTGGTTCAGCATTAAAAGCTTTAGAAGGC -- -GAT --- -GCTCAATACGAAGAAAAA- 564 SAUR-MRSA252 CGCTGGTTCAGCATTAAAAGCTTTAGAAGGC--- GAT---- GCTCAATACGAAGAAAAA- 564 70 SEPI-12228 CGCTGGTTCTGCATTAAAAGCATTAGAAGGC--- GAT ---- GCTGAATACGAACAAAAA- 564 SEPI-RP62A CGCTGGTTCTGCATTAAAAGCATTAGAAGGC--- GAT ---- GCTGAATACGAACAAAAA- 564 SMIT-DAS CCAAGGTTCAGCTCTTAAAGCTCTTGAAGGT--- GAT ---- GCTAAATACGAAGACATC- 432 SSAN-DAS CCAAGGTTCAGCTCTTAAAGCTCTTGAAGGT--- GAC ---- TCTAAATATGAAGACATC- 473 WO 2007/012131 PCT/AU2006/001056 -28 SMIT-NCTC12261 CCAAGGTTCAGCTCTTAAAGCCCTTGAAGGT--- GAC ---- ACTAAATACGAAGACATC- 573 SPNE-R6 CCAAGGTTCAGCACTTAAAGCTCTTGAAGGT--- GAC ---- TCTAAATACGAAGACATC- 573 SPYO-M1GAS CCAAGGTTCAGCTCTTAAAGCTCTTGAAGGC--- GAC ---- ACTAAATTTGAAGACATC- 573 SMUT-DAS TCAAGGTTCAGCTCTTAAAGCTCTTGAAGGT---GAT ---- ACTGCTCAAGAAGATATC- 473 5 SMUT-UA159 TCAAGGTTCAGCTCTTAAAGCTCTTGAAGGC--- GAT---- -ACTGCTCAAGAAGATATC- 573 HINF-RdKW20 ACGTGGTTCAGCATTACAAGCGTTAAACGGC ---GTA--- -GCAGAATGGGAAGAAAAA- 564 MCAT-DAS CAAAGGTTCAGCACTAGAAGCATTGAATGGT-- -TCTGACGGTAAATATGGTGAGCCTGC 420 BPER-Tohamal GAAGGGTTCGGCCAAGCTGGCGCTGGAAGGC--- GACAAGGGCGAACTGGGCGAGCAGGC 569 BPAR-12822 GAAGGGTTCGGOCAAGCTGGCGCTGGAAGGC ---GACAAGGGCGAACTGGGCGAGCAGGC 569 10 BCEP2-DAS CAAGGGTTCGGCAAAGCTGGCGCTGGAAGGC - -- GACAAGGGCGAGCTGGGCGAAACGGC 453 BPSE-1710b CAAGGGTTCGGCGAAGCTGGCGCTGGAAGGC--- GACAAGGGCGAGCTGGGCGAAGTGGC 569 SMAL-DAS CGCCGGTTCGGCCCGCCTGGCGCTGGAAGGC- --GACCAGAGCGACATCGGCGTGCCGGC 474 PAER-PA01 CATCGGTTCCGCGCTGATGGCGCTGGAAGGCAAGGATGACAACGGCATCGGCGTAAGCGC 572 KPNE-DAS TCGTGGTTCTGCTCTGAAAGCGCTGGAAGGC --- GAC ---- GCAGAGTGGG--AAGCGAA 447 15 MAVI-Kio GCGGGTGTCGGCGCTCAAGGCGCTCGAGGGC-- -GAC----GCCAAGTGGGTGGAGT--C 566 MAVI-paratub GCGGGTGTCGGCGCTCAAGGCGCTCGAGGGC--- GAC---- -GCCAAGTGGGTGGAGT--C 566 MAISpig-DAS GCGCGTCTCGGCGCTGAAGGCGCTCGAGGGC--- GAC---- -GCCAAGTGGGTGGAGT--C 461 MKAN-DAS GCGGGTCTCGGCACTGAAGGCCCTCGAGGGC - -- GAC- - --CCCAAGTGGGTGGAGT- -C 467 MTUB-H37Rv GCGGGTCTCGGCGCTCAAGGCGCTCGAGGGT--- GAC---- -GCGAAGTGGGTTGCCT--C 566 20 MTUB-CDC1551 GCGGGTCTCGGCGCTCAAGGCGCTCGAGGGT--- GAC---- -GCGAAGTGGGTTGCCT--C 566 MAVI-DAS CCGCGTCTCCGCGCTGAAGGCGCTGGAGGGT---GAC---- -CCGAAGTGGGTCAAGT--C 407 CIDP-NCTC13129 CCACATCTCCGCACTGAAGGCTCTTGAGGGC--- GAC ---- GAGAAGTGGACCCAGT--C 566 NMEN-MC58 ACAAGGTTCCGCACTGAAAGCCTTGGAAGGC -- -GAT --- -GCCGCTTACGAAGAAA--A 563 NMEN-Z2491 ACAAGGTTCCGCACTGAAAGCCTTGGAAGGC-- -GAT ----GCCGCTTACGAAGAAA--A 563 25 NMEN-DAS ACAAGGTTCTGCACTGAAAGCCTTGGAAGGC--- GAT---- -GCCGCTTATGAAGAGA--A 404 MPNE-HF2 -ATTGATGAATTAATGGCTTCAGTAGATAGCTACATCCCAACTCCAACAAGAGATACAGA 623 MPNE-M129 -ATCCATGATTTAATGAATGCAGTTGATGAATGGATTCCAACTCCTGAACGTGAAGTGGA 623 LPNE-Paris TATAGAGAAATTGGTTGAAACAATGGATTCATACATTCCTGAGCCAGTTAGAAACATAGA 642 30 LPNE2-DAS TATTGAGAAATTGGTTGAAACAATGGATTCATACATTCCTGAGCCAGTTAGAAATATAGA 512 LPNE-Philadelphial TATTGAGAAATTGGTTGAAACAATGGATTCATACATTCCTGAGCCAGTTAGAAACATAGA 629 LPNE-Lens TATTGAGAAATTAGTTGAAACAATGGATTCATACATTCCTGAGCCAGTTAGAAACATAGA 629 LLON-DAS AATAGAGAAATTGGTAGAGACTATGGATTCTTATATTCCAGAGCCTGTAAGAAACATTGA 513 FNUC-DAS -ATAATGGAACTTATGGATGCAGTAGATAGCTATATCCTACTCCTGAAAGAGCAGTAGA 501 35 CPNE-CWL029 --TTCGAGAACTTATGCAAGCTGTGGATGACAACATCCCTACACCAGAAAGAGAAATTGA 623 EFAE-DAS -ATCTTAGAATTAATGGCTGCAGTTGACGAATATATCCCAACTCCAGAACGTGATACTGA 500 EFAE-V583 -ATCTTAGAATTAATGGCTGCAGTTGACGAATATATCCCAACTCCAGAACGTGATACTGA 623 SAUR-Mu50 -ATCTTAGAATTAATGGAAGCTGTAGATACTTACATTCCAACTCCAGAACGTGATTCTGA 623 SAUR-N315 -ATCTTAGAATTAATGGAAGCTGTAGATACTTACATTCCAACTCCAGAACGTGATTCTGA 623 40 SAUR-MW2 -ATCTTAGAATTAATGGAAGCTGTAGATACTTACATTCCAACTCCAGAACGTGATTCTGA 623 SAUR-MSSA476 -ATCTTAGAATTAATGGAAGCTGTAGATACTTACATTCCAACTCCAGAACGTGATTCTGA 623 SAUR-MRSA252 -ATCTTAGAATTAATGGAAGCTGTAGATACTTACATTCCAACTCCAGAACGTGATTCTGA 623 SEPI-12228 -ATCTTAGACTTAATGCAAGCAGTTGATGATTACATTCCAACTCCAGAACGTGATTCTGA 623 SEPI-RP62A -ATCTTAGACTTAATGCAAGCAGTTGATGATTACATTCCAACTCCAGAACGTGATTCTGA 623 45 SMIT-DAS -ATCATGGACTTGATGAACACTGTTGATGAGTACATCCCAGAACCAGAACGCGATACTGA 491 SSAN-DAS -ATCATGGAATTGATGGACACTGTTGATGAGTACATCCCAGAACCAGAACGCGATACTGA 532 SMIT-NCTC12261 -GTTATGGAATTGATGAACACAGTTGATGAGTACATCCCAGAACCAGAACGTGACACTGA 632 SPNE-R6 -GTTATGGAATTGATGAACACAGTTGATGAGTATATCCCAGAACCAGAACGTGACACTGA 632 SPYO-M1GAS -ATCATGGAATTGATGGATACTGTTGATTCATACATTCCAGAACCAGAACGCGACACTGA 632 50 SMUT-DAS -ATCATGGAATTAATGCATACTGTTGATGACTACATTCCAGATCCAGAACGTGATACTGA 532 SMUT-UA159 -ATCATGGAATTAATGCATACTGTTGATGACTACATTCCAGATCCAGAACGTGATACTGA 632 HINF-RdKW20 -ATCCTTGAGTTAGCAAACCACTTAGATACTTACATCCCAGAACCAGAACGTGCGATTGA 623 MCAT-DAS TGTTCTAGAACTACTAGACACGCTAGATTCATACATCCCAGAGCCTGAGCGTGACATCGA 480 BPER-Tohamal GATTCTGTCGCTGGCGCAAGCGCTGGACACGTACATTCCGACGCCGGAGCGCGCGGTCGA 629 55 BPAR-12822 GATTCTGTCGCTGGCGCAAGCGCTGGACACGTACATTCCGACGCCGGAGCGCGCGGTCGA 629 BCEP2 -DAS GATCATGAACCTGGCCGACGCGCTGGACACGTACATCCCGACGCCGGAGCGCGCGGTGGA 513 BPSE-1710b GATCATGAACCTGGCCGACGCGCTGGACACGTACATCCCGACGCCGGAGCGTGCGGTCGA 629 SMAL-DAS CATCCTGAAGCTGGTCGACGCGCTGGACAGCTGGATTCCGGAGCCGGAGCGTGCGATCGA 534 PAER-PA01 CGTGCAGAAGCTGGTAGAGACCCTGGACTCCTACATTCCGGAGCCGGTTCGTGCCATCGA 632 60 KPNE-DAS AATCATCGAACTGGCTGGCCACCTGGATACCTATATCCCGGAACCAGAGCGTGCGATTGA 507 MAVI-KI0 CGTCGAGCAGCTGATGGAGGCCGTCGACGAGTCGATCCCGGACCCGGTCCGCGAGACGGA 626 MAVI-paratub CGTCGAGCAGCTGATGGAGGCCGTCGACGAGTCGATCCCGGACCCGGTCCGCGAGACGGA 626 MAISpig-DAS GGTCGAGCAGCTGATGGAGGCCGTCGACGAGTCGATCCCGGACCCCGTCCGTGAGACCGA 521 MKAN-DAS GGTGGAGCAGCTGATGGATGCGGTCGACGAGTCGATCCCCGACCCGGTCCGTGAGACCGA 527 65 MTUB-H37Rv TGTCGAGGAACTGATGAACGCGGTCGACGAGTCGATTCCGGACCCGGTCCGCGAGACCGA 626 MTUB-CDC1551 TGTCGAGGAACTGATGAACGCGGTCGACGAGTCGATTCCGGACCCGGTCCGCGAGACCGA 626 MAVI-DAS GGTTGAGGACCTCATGGAGGCCGTCGACGAGTCGATCCCGGATCCGGTTCGCGAGACCGA 467 CIDP-NCTC13129 CATCATCGACCTCATGCAGGCTTGCGATGATTCCATCCCAGACCCAGAGCGTGAGACCGA 626 NMEN-MC58 AATCTTCGAACTGGCTGCCGCATTGGACAGCTACATCCCGACTCCCGAGCGAGCCGTGGA 623 70 NMEN-Z2491 AATCTTCGAATTGGCTGCTGCATTGGACAGCTACATCCCGACTCCCGAGCGTGCCGTGGA 623 NMEN-DAS AATCTTCGAACTGGCTGCCGCATTGGACAGCTACATCCCGACTCCCGAGCGTGCCGTGGA 464 WO 2007/012131 PCT/AU2006/001056 - 29 MPNE-HF2 CAAACCTTTCTTATTAGCGGTAGAAGACGTTATGACTATTACTGGTAGAGGTACTGTAGT 683 MPNE-M129 CAAACCCTTCTTGTTGGCAATCGAAGACACCATGACGATTACTGGCCGTGGTACCGTGGT 683 LPNE-Paris CAAGCCATTTTTGTTACCGATTGAAGACGTATTTTCAATTTCTGGACGCGGAACAGTGGT 702 LPNE2-DAS CAAGCCATTTTTGTTACCGATTGAAGACGTATTTTCAATTTCTGGACGCGGAACAGTGGT 572 5 LPNE-Philadelphial CAAGCCATTTTTGTTGCCGATTGAAGACGTATTTTCAATTTCTGGACGCGGAACAGTGGT 689 LPNE-Lens CAAGCCATTCTTGTTGCCGATTGAAGACGTGTTTTCAATTTCTGGACGCGGAACAGTGGT 689 LLON-DAS CAAATCGTTCTTATTACCGATTGAAGATGTATTTTCAATATCTGGCCGAGGAACAGTAGT 573 FNUC-DAS TCAACCATTCTTGATGCCAATAGAAGACGTTTTCACTATCACAGGAAGAGGAACAGTTGT 561 CPNE-CWL029 TAAGCCTTTCTTAATGCCTATCGAAGACGTATTCTCAATCTCTGGTCGTGGTACTGTGGT 683 10 EFAE-DAS CAAACCATTCATGATGCCAGTCGAAGACGTATTCTCAATCACTGGACGTGGTACTGTTGC 560 EFAE-V583 CAAACCATTCATGATGCCAGTCGAAGACGTATTCTCAATCACTGGACGTGGTACTGTTGC 683 SAUR-MuS0 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SAUR-N315 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SAUR-MW2 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 15 SAUR-MSSA476 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SAUR-MRSA252 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SEPI-12228 CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SEPI-RP62A CAAACCATTCATGATGCCAGTTGAGGACGTATTCTCAATCACTGGTCGTGGTACTGTTGC 683 SMIT-DAS CAAACCATTGCTTCTTCCAGTCGAAGACGTATTCTCAATCACTGGACGTGGTACTGTAGC 551 20 SSAN-DAS CAAGCCATTGCTTCTTCCAGTCGAAGACGTATTCTCAATCACTGGTCGTGGTACAGTTGC 592 SMIT-NCTC12261 CAAACCATTGCTTCTTCCAGTCGAAGACGTATTCTCAATCACTGGTCGTGGTACAGTTGC 692 SPNE -R6 CAAACCATTGCTTCTTCCAGTCGAGGACGTATTCTCAATCACTGGACGTGGTACAGTTGC 692 SPYO-M1GAS CAAACCATTGCTTCTTCCAGTCGAAGACGTATTCTCAATTACAGGTCGTGGTACAGTTGC 692 SMUT-DAS TAAGCCACTCCTTCTTCCAGTCGAAGATGTTTTCTCAATCACTGGTCGTGGTACTGTTGC 592 25 SMUT-UA159 CAAGCCGCTCCTTCTTCCAGTCGAAGATGTTTTCTCAATCACTGGTCGTGGTACTGTTGC 692 HINF-RdKW20 CCAACCGTTCCTTCTTCCAATCGAAGATGTGTTCTCAATCTCAGGTCGTGGTACTGTAGT 683 MCAT-DAS TAAGTCATTCCTAATGCCAATCGAAGATGTCTTCTCAATCTCAGGTCGTGGTACTGTTGT 540 BPER-Tohamal CGGTGCGTTCCTGATGCCGGTGGAAGACGTGTTCTCGATCTCGGGCCGTGGCACGGTGGT 689 BPAR-12822 CGGTGCGTTCCTGATGCCGGTGGAAGACGTGTTCTCGATCTCGGGCCGTGGCACGGTGGT 689 30 BCEP2 -DAS CGGTACGTTCCTGATGCCGGTGGAAGACGTGTTCTCGATCTCGGGCCGCGGTACGGTGGT 573 BPSE-1710b CGGCGCGTTCCTGATGCCGGTGGAAGACGTGTTCTCGATCTCGGGCCGTGGTACGGTGGT 689 SMAL-DAS CAAGCCGTTCCTGATGCCGGTGGAAGACGTGTTCTCGATCTCGGGCCGCGGCACCGTGGT 594 PAER-PA01 CCAGCCGTTCCTGATGCCGATCGAAGACGTGTTCTCGATCTCCGGCCGCGGTACCGTGGT 692 KPNE-DAS CAAGCCGTTCCTGCTGCCGATCGAAGACGTATTCTCCATCTCCGGTCGTGGTACCGTTGT 567 35 MAVI-K10 CAAGCCGTTCCTGATGCCGGTGGAGGACGTCTTCACCATCACCGGTCGTGGCACGGTGGT 686 MAVI-paratub CAAGCCGTTCCTGATGCCGGTGGAGGACGTCTTCACCATCACCGGTCGTGGCACGGTGGT 686 MAISpig-DAS GAAGCCGTTCCTGATGCCGGTGGAGGACGTCTTCACGATCACCGGTCGTGGCACCGTGGT 581 MKAN-DAS CAAGCCGTTCCTGATGCCCGTCGAGGACGTCTTCACGATCACCGGCCGCGGCACCGTGGT 587 MTUB-H37Rv CAAGCCGTTCCTGATGCCGGTCGAGGACGTCTTCACCATTACCGGCCGCGGAACCGTGGT 686 40 MTUB-CDC1551 CAAGCCGTTCCTGATGCCGGTCGAGGACGTCTTCACCATTACCGGCCGCGGAACCGTGGT 686 MAVI-DAS CAAGCCGTTCCTGATGCCCGTCGAGGACGTCTTCACCATCACCGGTCGTGGCACCGTGGT 527 CIDP-NCTC13129 CAAGCCATTCCTCATGCCTATCGAGGACATCTTCACCATCACCGGCCGCGGTACCGTTGT 686 NMEN-MC58 CAAACCGTTCCTGCTGCCTATCGAAGACGTGTTCTCCATTTCCGGCCGCGGTACAGTAGT 683 NMEN-Z2491 CAAACCTTTCTTGTTGCCTATCGAAGACGTATTCTCTATTTCCGGTCGTGGTACAGTAGT 683 45 NMEN-DAS CAAACCTTTCCTGCTGCCTATCGAAGACGTGTTCTCCATTTCCGGCCGAGGTACAGTAGT 524 MPNE-HF2 AACTGGTAGAGTTGAAAGAGGTACTTTAAAATTAAACGATGAAGTTGAAATCGTTGGTAT 743 MPNE -M12 9 TACCGGTCGGGTTGAACGTGGTGAATTGAAAGTAGGTCAAGAAATTGAAATCGTTGGTTT 743 LPNE-Paris AACTGGTCGTGTTGAGAGTGGAATTGTTAAAGTTGGTGAGGAAGTTGAAATTGTTGGAAT 762 50 LPNE2-DAS AACTGGTCGTGTTGAGAGTGGAATTGTTAAAGTTGGTGAGGAAGTTGAAATTGTTGGAAT 632 LPNE-Philadelphial AACTGGTCGTGTAGAGAGTGGAATTGTTAAAGTTGGTGAGGAAGTTGAAATTGTTGGAAT 749 LPNE-Lens AACTGGTCGTGTTGAGAGTGGAATTGTTAAAGTTGGTGAGGAAGTTGAAATTGTTGGAAT 749 LLON-DAS AACAGGACGTATCGAAAGCGGAATTATCAAAGTTGGCGAAGAGATCGAAATTGTAGGAAT 633 FNUC-DAS TACAGGAAGAGTTGAAAGAGGAATCATCAAAGTTGGAGAAGAAATTGAAATAGTTGGAAT 621 55 CPNE-CWL029 TACAGGAAGAATCGAGCGTGGAATCGTTAAAGTTTCTGATAAAGTTCAGCTCGTGGGATT 743 EFAE-DAS TACAGGACGTGTTGAACGTGGTGAAGTTCGCGTTGGTGACGAAGTTGAAATCGTTGGTAT 620 EFAE-V583 TACAGGCCGTGTTGAACGTGGTGAAGTTCGCGTTGGTGACGAAGTTGAAATCGTTGGTAT 743 SAUR-MuS0 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTTT 743 SAUR-N315 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTTT 743 60 SAUR-MW2 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTTT 743 SAUR-MSSA476 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTTT 743 SAUR-MRSA252 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTTT 743 SEPI-12228 TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTAT 743 SEPI-RP62A TACAGGCCGTGTTGAACGTGGTCAAATCAAAGTTGGTGAAGAAGTTGAAATCATCGGTAT 743 65 SMIT-DAS ATCAGGACGTATCGACCGTGGTATCGTTAAAGTCAACGACGAAATCGAAATCGTTGGTAT 611 SSAN-DAS TTCAGGACGTATCGACCGTGGTATCGTTAAAGTCAACGACGAAATCGAAATCGTTGGTAT 652 SMIT-NCTC12261 TTCAGGACGTATCGACCGTGGTATCGTTAAAGTCAACGACGAAATCGAAATCGTTGGTAT 752 SPNE-R6 TTCAGGACGTATCGACCGTGGTATCGTTAAAGTCAACGACGAAATCGAAATCGTTGGTAT 752 SPYO-M1GAS TTCAGGACGTATCGACCGTGGTACTGTTCGTGTCAACGACGAAATCGAAATCGTTGGTAT 752 70 SMUT-DAS TTCAGGACGTATTGATCGTGGTACTGTTAAAGTTAACGATGAAGTTGAAATCGTTGGTAT 652 SMUT-UA159 TTCAGGACGTATTGATCGTGGTACTGTTAAAGTTAACGATGAAGTTGAAATCGTTGGTAT 752 HINF-RdKW20 AACAGGTCGTGTAGAACGAGGTATTATCCGTACAGGTGATGAAGTAGAAATCGTCGGTAT 743 MCAT-DAS AACTGGCCGTGTTGAATCAGGCATTATTAAAGTTGGTGATGAAATTGAAATCATCGGTAT 600 WO 2007/012131 PCT/AU2006/001056 - 30 BPER-TohamaI GACTGGCCGTATCGAGCGCGGCGTGGTGAAGGTTGGCGAGGAAATCGAAATCGTGGGCAT 749 BPAR-12822 GACTGGCCGTATCGAGCGCGGCGTGGTGAAGGTTGGCGAGGAAATCGAAATCGTGGGTAT 749 BCEP2-DAS GACGGGTCGTGTGGAGCGCGGCGTGGTGAAGGTCGGTGAGGAAATCGAAATCGTCGGTAT 633 BPSE-1710b GACGGGTCGTGTCGAGCGCGGCGTGATCAAGGTTGGCGAGGAAATCGAAATCGTCGGTAT 749 5 SMAL-DAS GACCGGTCGTATCGAGCGCGGCGTGATCAAGGTTGGCGACGAAATCGAAATCGTCGGCAT 654 PAER-PA01 AACCGGTCGTGTAGAGCGCGGCATCATCAAGGTCCAGGAAGAAGTGGAAATCGTCGGCAT 752 KPNE-DAS TACCGGTCGTGTAGAGCGCGGTATCATCAAAGTAGGTGAAGAAGTTGAAATCGTTGGTAT 627 MAVI-K10 CACCGGCCGTGTCGAGCGCGGCGTGATCAACGTGAACGAGGAAGTCGAGATCGTCGGCAT 746 MAVI-paratub CACCGGCCGTGTCGAGCCGCGGCGTGATCAACGTGAACGAGGAAGTCGAGATCGTCGGCAT 746 10 MAISpig-DAS CACCGGTCGTGTCGAGCGCGGTGTGATCAACGTGAACGAGGAAGTCGAGATCGTCGGTAT 641 MKAN-DAS CACCGGTCGTGTGGAGCGCGGCGTGGTCAACGTCAACGAGGAAGTCGAGATCGTCGGCAT 647 MTUB-H37Rv CACCGGACGTGTGGAGCGCGGCGTGATCAACGTGAACGAGGAAGTTGAGATCGTCGGCAT 746 MTUB-CDC1551 CACCGGACGTGTGGAGCGCGGCGTGATCAACGTGAACGAGGAAGTTGAGATCGTCGGCAT 746 MAVI-DAS GACCGGTCGCGTCGAGCGTGGCGTGATCAACGTCAACGAAGAGGTCGAGATCGTCGGCAT 587 15 NCTC13129 TACCGGCCGTGTTGAGCGTGGCTCCCTGAAGGTCAACGAGGACGTCGAGATCATCGGTAT 746 NMEN-MC58 AACCGGCCGTGTAGAGCGCGGTATCATCCACGTTGGTGACGAGATTGAAATCGTCGGTCT 743 NMEN-Z2491 AACCGGTCGTGTAGAGCGCGGTATCATCCACGTCGGTGACGAGATCGAAATCGTCGGTCT 743 NMEN-DAS AACCGGCCGTGTAGAGCGCGGTATCATCCACGTTGGTGACGAGATTGAAATCGTCGGTCT 584 20 MPNE-HF2 --- CCATGATACTAGAAAAGCAGTTGTTACTGGTATGGAAATGTTAAGAAAAACATTAGA 800 MPNE-M129 - - -ACGTCCAATCCGTAAAGCAGTTGTTACCGGAATCGAAATGTTCAAAAAGGAACTTGA 800 LPNE-Paris --- AAGAGACACTCAAAAGACGACTTGTACGGGTGTTGAGATGTTCCGTAAATTACTTGA 819 LPNE2-DAS ---AAGAGACACCCAAAAGACGACTTGTACGGGTGTTGAGATGTTCCGTAAATTACTTGA 689 LPNE-Philadelphial --- AAGAGACACCCAAAAGACGACTTGTACGGGTGTTGAGATGTTCCGTAAATTACTTGA 806 25 LPNE-Lens --- AAGAGACACCCAAAAGACGACTTGTACTGGTGTTGAGATGTTCCGTAAATTACTTGA 806 LLON-DAS --- TCGTGATACTGCAAAGACTACCTGTACTGGTGTTGAGATGTTCCGTAAGTTATTAGA 690 FNUC-DAS --- TAAACCTACAACTAAAACAACTTGTACAGGGGTTGAAATGTTTAGAAAACTTCTTGA 678 CPNE - CWLO 29 - - -AGGAGAGACTAAAGAAACAATCGTTACTGGAGTCGAAATGTTCAGGAAAGAACTTCC 800 EFAE-DAS TAAAGACGAAACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 680 30 EFAE-V583 TAAAGACGAAACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 803 SAUR-Mu5O --- ACATGACACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 800 SAUR-N315 --- ACATGACACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 800 SAUR-MW2 --- ACATGACACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 800 SAUR-MSSA476 --- ACATGACACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 800 35 SAUR-MRSA252 ---ACATGACACATCTAAAACAACTGTTACAGGTGTTGAAATGTTCCGTAAATTATTAGA 800 SEPI-12228 --- GCACGAAACTTCTAAAACAACTGTTACTGGTGTAGAAATGTTCCGTAAATTATTAGA 800 SEPI-RP62A --- GCACGAAACTTCTAAAACAACTGTTACTGGTGTAGAAATGTTCCGTAAATTATTAGA 800 SMIT-DAS TAAAGAAGAAATCCAAAAAGCGGTTGTTACTGGTGTTGAAATGTTCCGTAAACAACTTGA 671 SSAN-DAS CAAAGAAGAAATCCAAAAAGCAGTTGTTACTGGTGTTGAAATGTTCCGTAAACAGCTTGA 712 40 SMIT-NCTC12261 CAAAGAAGAAACTCAAAAAGCAGTTGTTACTGGTGTTGAAATGTTCCGTAAACAACTTGA 812 SPNE-R6 CAAAGAAGAAACTCAAAAAGCAGTTGTTACTGGTGTTGAAATGTTCCGTAAACAACTTGA 812 SPYO-M1GAS CAAAGAAGAAACTAAAAAAGCTGTTGTTACTGGTGTTGAAATGTTCCGTAAACAACTTGA 812 SMUT-DAS CCGTGATGACATTCAAAAAGCTGTTGTTACTGGTGTTGAAATGTTCCGTAAACAATTGGA 712 SMUT-UA159 CCGTGATGACATTCAAAAAGCTGTTGTTACTGGTGTTGAAATGTTCCGTAAACAATTGGA 812 45 HINF -RdKW20 --- CAAAGATACAGCGAAAACTACTGTAACGGGTGTTGAAATGTTCCGTAAATTACTTGA 800 MCAT-DAS --- CAAACCAACTACTAAAACCACTTGTACTGGTGTTGAAATGTTCCGTAAGCTGCTAGA 657 BPER-TohamaI CAAGCCGACGG--- TGAAGACGACCTGCACGGGCGTGGAGATGTTCCGCAAGCTGCTGGA 806 BPAR-12822 CAAGCCGACGG--- TGAAGACGACCTGCACGGGCGTGGAGATGTTCCGCAAGCTGCTGGA 806 BCEP2-DAS CAAGCCGACGG--- TGAAGACGACCTGCACGGGCGTTGAAATGTTCCGCAAGCTGCTGGA 690 50 BPSE-1710b CAAGGCGACGG--- CGAAGACGACCTGCACGGGCGTGGAAATGTTCCGCAAGCTGCTGGA 806 SMAL-DAS CCGTCCGGTGC- - - AGAAGACCACCGTGACCGGCGTTGAAATGTTCCGCAAGCTGCTGGA 711 PAER-PA01 CAAGGCGACCA--- CCAAGACTACCTGCACCGGCGTTGAAATGTTCCGCAAGCTGCTCGA 809 KPNE-DAS CAAAGAAACCG--- CGAAAACCACCTGTACTGGCGTTGAAATGTTCCGCAAACTGCTGGA 684 MAVI-Ki0 CCGCCCGTCCAGCACCAAGACCACGGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 806 55 MAVI-paratub CCGCCCGTCCAGCACCAAGACCACGGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 806 MAISpig-DAS CAAGCCGACCAGCACCAAGACCACCGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 701 MKAN-DAS CCGTCCGACCACCACCAAGACCACGGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 707 MTUB-H37Rv TCGCCCATCGACCACCAAGACCACCGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 806 MTUB-CDC1551 TCGCCCATCGACCACCAAGACCACCGTCACCGGTGTGGAGATGTTCCGCAAGCTGCTCGA 806 60 MAVI-DAS CCGCCCGACCACGACCAAGACCACCGTCACCGGTGTGGAAATGTTCCGCAAGCTGCTCGA 647 CIDP-NCTC13129 CCGCGAGAAGGCTACCACCACCACCGTTACCGGTATCGAGATGTTCCGTAAGCTTCTCGA 806 NMEN-MC58 GAAAGAAACCC--- AAAAAACCACTTGTACCGGTGTTGAAATGTTCCGCAAACTGCTGGA 800 NMEN-Z2491 GAAAGAAACTC --- AAAAAACCACTTGTACCGGTGTTGAAATGTTCCGCAAACTGCTGGA 800 65 NMEN-DAS GAAAGAAACCC--- AAAAAACCACCTGTACCGGTGTTGAAATGTTCCGCAAACTGCTGGA 641 MPNE -HF2 CGAAGTAAAAGCTGGGGATAACGCTGGTATCTTATTAAGAGGTATTGATAGAAAAGATGT 860 MPNE-M129 TTCAGCAATGGCTGGGGACAACGCTGGGGTATTACTCCGTGGTGTGGACCGTAAAGAAGT 860 LPNE-Paris TGAAGGTCGAGCTGGTGATAACGTTGGAGTGTTATTACGAGGTACGAAGCGAGATGAAGT 879 LPNE2-DAS TGAAGGTCGAGCTGGTGATAACGTTGGTGTGTTATTACGAGGTACGAAGCGAGATGAAGT 749 70 LPNE-Philadelphial TGAAGGTCGAGCTGGTGATAACGTTGGTGTGTTATTACGAGGTACGAAGCGAGATGAAGT 866 LPNE-Lens TGAAGGTCGAGCTGGTGATAACGTTGGTGTGTTATTACGCGGTACGAAGCGAGATGAAGT 866 LLON-DAS CGAAGGACGTGCAGGTGATAACGTTGGTATATTACTCCGTGGAACAAAACGAGACGAAGT 750 FNUC-DAS TCAAGGTCAAGCAGGAGATAATATCGGAGTATTATTAAGAGGAACTAAGAAAGAAGAAGT 738 WO 2007/012131 PCT/AU2006/001056 -31 CPNE-CWL029 TGAAGGTCGTGCAGGAGAAAACGTTGGTTTACTCCTCAGAGGTATTGGAAAGAACGATGT 860 EFAE-DAS CTACGCTGAAGCAGGCGACAACATCGGTGCTTTATTACGTGGTGTAGCACGTGAAGATAT 740 EFAE-V583 CTACGCTGAAGCAGGCGACAACATCGGTGCTTTATTACGTGGTGTAGCACGTGAAGATAT 863 SAUR-Mu50 CTACGCTGAAGCTGGTGACAACATTGGTGCATTATTACGTGGTGTTGCTCGTGAAGACGT 860 5 SAUR-N315 CTACGCTGAAGCTGGTGACAACATTGGTGCATTATTACGTGGTGTTGCTCGTGAAGACGT 860 SAUR-MW2 CTACGCTGAAGCTGGTGACAACATTGGTGCATTATTACGTGGTGTTGCTCGTGAAGACGT 860 SAUR-MSSA476 CTACGCTGAAGCTGGTGACAACATTGGTGCATTATTACGTGGTGTTGCTCGTGAAGACGT 860 SAUR-MRSA252 CTACGCTGAAGCTGGTGACAACATTGGTGCATTATTACGTGGTGTTGCTCGTGAAGACGT 860 SEPI-12228 CTACGCTGAAGCTGGTGACAACATCGGTGCTTTATTACGTGGTGTTGCACGTGAAGACGT 860 10 SEPI-RP62A CTACGCTGAAGCTGGTGACAACATCGGTGCTTATTACGTGGTGTTGCACGTGAAGACGT 860 SMIT-DAS CGAATGTCTTGCAGGGGACAACGTTGGTGTGCTTCTTCGTGGTATCCAACGTGATGAAAT 731 SSAN-DAS CGAAGGTCTTGCAGGGGACAACGTAGGTGTGCTTCTCCGTGGTATCCAACGTGATGAAAT 772 SMIT-NCTC12261 CGAAGGTCTTGCCGGAGATAATGTAGGTGTCCTTCTTCGTGGTGTTCAACGTGATGAAAT 872 SPNE-R6 CGAAGGTCTTGCTGGAGATAACGTAGGTGTCCTTCTTCGTGGTGTTCAACGTGATGAAAT 872 15 SPYO-M1GAS CGAAGGTCTTGCAGGAGACAACGTAGGTATCCTTCTTCGTGGTGTTCAACGTGACGAAAT 872 SMUT-DAS TGAAGGTATTGCAGGGGATAATGTTGGTGTTCTCCTTCGTGGTATCCAACGTGATGAAAT 772 SMUT-UA159 TGAAGGTATTGCAGGGGATAATGTTGGTGTTCTCCTTCGTGGTATCCAACGTGATGAAAT 872 HINF-RdKW20 CGAAGGTCGTGCAGGTGAAAACATCGGTGCATTATTACGTGGTACCAAACGTGAAGAAAT 860 MCAT-DAS CGAAGGTCGTGCAGGTGAGAACTGTGGTATCCTACTACGTGGTACTAAGCGTGAAGAAGT 717 20 BPER-Tohamal CCAGGGCCAGGCGGGCGACAACGTGGGTATCTTGCTGCGCGGCACCAAGCGTGAAGACGT 866 BPAR-12822 CCAGGGCCAGGCGGGCGACAACGTGGGTATCTTGCTGCGCGGCACCAAGCGTGAAGACGT 866 BCEP2-DAS CCAGGGTCAGGCAGGCGACAACGTCGGTATCCTGCTGCGCGGCACGAAGCGTGAAGACGT 750 BPSE-1710b TCAGGGTCAGGCGGGCGACAACGTCGGTATCCTGCTGCGCGGCACGAAGCGTGAAGACGT 866 SMAL-DAS CCAGGGTCAGGCAGGCGACAACGCTGGCCTGCTGCTGCGCGGCACCAAGCGTGACGACGT 771 25 PAER-PA01 CGAAGGTCGTGCTGGTGAGAACGTTGGTATCCTGCTGCGTGGCACCAAGCGTGAAGACGT 869 KPNE-DAS CGAAGGCCGTGCTGGTGAGAACGTAGGTGTTCTGCTGCGTGGTATCAAACGTGAAGAAAT 744 MAVI-K1O CCAGGGCCAGGCCGGTGACAACGTCGGTCTGCTGCTGCGTGGTATCAAGCGTGAGGACGT 866 MAVI-paratub CCAGGGCCAGGCCGGTGACAACGTCGGTCTGCTGCTGCGTGGTATCAAGCGTGAGGACGT 866 MAISpig-DAS CCAGGGACAGGCCGGCGACAACGTCGGACTGTTGCTGCGTGGCATCAAGCGCGAGGACGT 761 30 MKAN-DAS CCAGGGTCAGGCCGGTGACAACGTCGGGCTGTTGCTGCGTGGTGTCAAGCGTGAGGACGT 767 MTUB-H37Rv CCAGGGCCAGGCGGGCGACAACGTTGGTTTGCTGCTGCGGGGCGTCAAGCGCGAGGACGT 866 MTUB-CDC1551 CCAGGGCCAGGCGGGCGACAACGTTGGTTTGCTGCTGCGGGGCGTCAAGCGCGAGGACGT 866 MAVI-DAS CCAGGGCCAGGCCGGCGACAACGTCGGTCTGCTGGTTCGTGGCATCAAGCGCGAGGACGT 707 NCTC13129 CTACACCGAGGCTGGCGACAACTGTGGTCTGCTTCTCCGTGGCGTTAAGCGCGAAGACGT 866 35 NMEN-MC58 CGAAGGTCAGGCGGGCGACAACGTAGGCGTATTGCTGCGCGGTACCAAACGTGAAGACGT 860 NMEN-Z2491 CGAAGGTCAAGCAGGCGACAACGTAGGCGTATTGCTGCGCGGTACCAAACGTGAAGACGT 860 NMEN-DAS CGAAGGTCAGGCGGGCGACAACGTACGCGTATTGCTGCGCGGTACCAAACGTGAAGACGT 701 MPNE-HF2 TGAACGTGGACAAGTATTAGCTAAACC-TGGTTCAATTAAACCTCACAAACAATTTGAAG 919 40 MPNE-M129 GGAACGTGGTCAAGTGTTAGCTAAACC-AGGTTCGATTAAACCGCACAAGAAATTTAAAG 919 LPNE-Paris GGAGCGTGGACAGGTATTGGCAAAGCC-AGGTACCATCAAGCCACACACCAAGTTTGAAG 938 LPNE2-DAS GGAGCGTGGACAGGTATTGGCTAAGCC-AGGTACCATCAAGCCACACACCAAGTTTGAAG 808 LPNE-Philadelphial GGAGCGTGGACAGGTATTGGCGAAGCC-AGGAACCATCAAGCCACACACCAAGTTTGAAG 925 LPNE-Lens GGAGCGCGGACAGGTATTGGCTAAGCC-AGGAACCATCAAGCCACACACCAAGTTTGAAG 925 45 LLON-DAS TGAGCGTGGTCAGGTATTAGCCAAACC-AGGTACAATTAAGCCTCACACTAAATTTGAAG 809 FNUC-DAS TGAAAGAGGACAAGTTCTTGCTAAACC-AGGAAGTATCCACCCTCATACAAACTTTAAAG 797 CPNE-CWL029 TGAAAGAGGTATGGTGGTTTGTCAGCC-TAACAGCGTGAAGCCTCATACGAAATTTAAGT 919 EFAE-DAS CGAACGTGGACAAGTATTAGCTAAACC-AGCTACAATCACTCCACACACAAAATTCAAAG 799 EFAE-V583 CGAACGTGGACAAGTATTAGCTAACC-AGCTACAATCACTCCACACACAAAATTCAAAG 922 50 SAUR-Mu50 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCAATTACACCACATCTGAATTTAAAG 919 SAUR-N315 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCAATTACACCACATACTGAATTTAAAG 919 SAUR-MW2 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCAATTACACCACATACTGAATTCAAAG 919 SAUR-MSSA476 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCAATTACACCACATACTGAATTCAAAG 919 SAUR-MRSA252 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCAATTACACCACATACTGAATTCAAAG 919 55 SEPI-12228 ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCTATTACACCACACACAAAATTCAAAG 919 SEPI-RP62A ACAACGTGGTCAAGTATTAGCTGCTCC-TGGTTCTATTACACCACACACAAAATTCAAAG 919 SMIT-DAS CGAACGTGGACAAGTTATCGCTAAACC-AGGTTCAATCAACCCACACACTAAATTCAAAG 790 SSAN-DAS CGAACGTGGACAAGTTATCGCTAAACC-AGGTTCAATCAACCCACACACTAAATTCAAGG 831 SMIT-NCTC12261 CGAACGTGGACAAGTTATTGCTAAACC-AGGTTCAATCAACCCACACACTAAATTCAAAG 931 60 SPNE-RG CGAACGTGGACAAGTTATCGCTAAACC-AGGTTCAATCAACCCACACACTAAATTCAAAG 931 SPYO-M1GAS CGAACGTGGTCAAGTTATTGCTAAACC-AAGTTCAATCAACCCACACACTAAATTCAAAG 931 SMUT-DAS CGAACGTGGTCAAGTTCTTGCTAAACC-AGGTTCAATTCACCCACATACTAAATTCAAAG 831 SMUT-UA159 CGAACGTGGTCAAGTTCTTGCTAAACC-AGGTTCAATTCACCCACATACTAAATTCAAAG 931 HINF-RdKW20 CGAACGTGGTCAAGTATTAGCGAAACC-AGGTTCAATCACACCACACACTGACTTCGAAT 919 65 MCAT-DAS TCAACGTGGTCAAGTATTGGCTAAGCC-AGGTTCAATCACCCCACACACCAAGTTTGATG 776 BPER-TohamaI CGAGCGTGGCCAGGTGCTGGCCAAGCC-GGGTTCGATCAACCCGCACACGGACTTCACGG 925 BPAR-12822 CGAGCGTGGCCAGGTGCTGGCCAAGCC-GGGTTCGATCAACCCGCACACGGACTTCACGG 925 BCEP2-DAS GGAGCGCGGTCAGGTTCTGGCGAAGCC-GGGTTCGATCACGCCGCACACGCACTTCACGG 809 BPSE-1710b GGAGCGCGGCCAGGTTCTGGCGAAGCC-GGGTTCGATCACGCCGCACACGCACTTCACGG 925 70 SMAL-DAS CGAGCGTGGCCAGGTGCTGGCCAAGCC-GGGCACGATCAAGCCGCACACCAAGTTCGAAG 830 PAER-PA01 AGAGCGTGGCCAGGTACTGGCCAAGCC-GGGCACCATCAAGCCGCACACCAAGTTCGAGT 928 KPNE-DAS CGAACGTGGTCAGGTACTGGCTAAGCC-GGGCACCATCAACCCGCACACCAAGTTCGAAT 803 MAVI-K10 CGAGCGCGGTCAGGTCGTCACCAAGCC-CGGCACCACCACGCCGCACACCGAGTTCGAGG 925 WO 2007/012131 PCT/AU2006/001056 - 32 MAVI-paratub CGAGCGCGGTCAGGTCGTCACCAAGCC-CGGCACCACCACGCCGCACACCGAGTTCGAGG 925 MAISpig-DAS CGAGCGCGGTCAGGTCGTCGTGAAGCC-CGGCACCACCACGCCGCACACCGAGTTCGAGG 820 MKAN-DAS CGAGCGCGGCCAGGTCGTCATCAAGCC-CGGCACCACAACCCCGCACACCGAGTTCGAGG 826 MTUB-H37Rv CGAGCGTGGCCAGGTTGTCACCAAGCC-CGGCACCACCACGCCGCACACCGAGTTCGAAG 925 5 MTUB-CDC1551 CGAGCGTGGCCAGGTTGTCACCAAGCC-CGGCACCACCACGCCGCACACCGAGTTCGAAG 925 MAVI-DAS CGAGCGTGGCCAGGTTGTGGTCAAGCC-CGGCACCACCACCCCGCACACCGAGTTCGAGG 766 NCTC13129 TGAGCGTGGCCAGGTTGTTGTTAAGCC-AGGCGCTTACACCCCTCACACCGAGTTCGAGG 925 NMEN-MC58 GGAACGCGGTCAGGTATTGGCTAAACC-GGGTACTATCACTCCTCACACCAAATTCAAAG 919 NMEN-Z2491 AGAGCGTGGTCAAGTATTGGCTAAACC-GGGTACAATCACTCCTCACACCAAGTTCAAAG 919 10 NMEN-DAS GGAACGCGGTCAGGTATTGGCCAAACCCGGGTACTATCACTCCTCACACCAAGTTCAAAG 761 MPNE-HF2 CAGAAATCTATGCTCTTAAAAAAGAAGAAGGTGGAAGACATACTCCAGTATTAAATGGAT 979 MPNE-M129 CGGAAATCTATGCTTTAAAGAAGGAAGAAGGTGGTCGTCACACCGGTTTCTTAAACGGTT 979 LPNE-Paris CAGAAGTGTATGTGTTATCCAAGGAAGAAGGCGGACGTCACACACCATTCTTTAATGGAT 998 15 LPNE2-DAS CAGAAGTGTATGTATTATCCAAGGAAGAAGGCGGACGTCACACACCATTCTTTAATGGAT 868 LPNE-Philadelphial CAGAAGTGTATGTATTATCCAAGGAAGAAGGCGGACGTCACACTCCATTCTTTAATGGAT 985 LPNE-Lens CAGAAGTGTATGTATTATCGAAGGAAGAAGGCGGACGTCACACTCCATTCTTTAATGGAT 985 LLON-DAS CGGAAGTATACGTGTTATCTAAAGAAGAAGGTGGACGACATACCCCGTTTTTCAATGGAT 869 FNUC-DAS GTGAAGTCTATGTATTAACTAAAGATGAAGGAGGAAGACACACTCCATTTTTCACAGGAT 857 20 CPNE-CWL029 CAGCTGTTTACGTTCTTCAGAAAGAAGAAGGCGGACGTCATAAGCCTTTCTTCAGCGGAT 979 EFAE-DAS CTGAAGTATACGTATTATCAAAAGAAGAAGGCGGACGTCACACTCCATTCTTCACTAACT 859 EFAE-V583 CTGAAGTATACGTATTATCAAAAGAAGAAGGCGGACGTCACACTCCATTCTTCACTAACT 982 SAUR-Mu5 0 CAGAAGTATACGTATTATCAAAAGACGAAGGTGGACGTCACACTCCATTCTTCTCAAACT 979 SAUR-N315 CAGAAGTATACGTATTATCAAAAGACGAAGGTGGACGTCACACTCCATTCTTCTCAAACT 979 25 SAUR-MW2 CAGAAGTATACGTATTATCAAAAGACGAAGGTGGACGTCACACTCCATTCTTCTCAAACT 979 SAUR-MSSA476 CAGAAGTATACGTATTATCAAAAGACGAAGGTGGACGTCACACTCCATTCTTCTCAAACT 979 SAUR-MRSA252 CAGAAGTATACGTATTATCAAAAGACGAAGGTGGACGTCACACTCCATTCTTCTCAAACT 979 SEPI-12228 CTGAAGTATACGTATTATCTAAAGATGAAGGTGGACGTCACACTCCATTCTTCACTAACT 979 SEPI-RP62A CTGAAGTATACGTATTATCTAAAGATGAAGGTGGACGTCACACTCCATTCTTCACTAACT 979 30 SMIT-DAS GTGAAGTTTACATCCTTACTAAAGAAGAAGGTGGACGTCATACTCCATTCTTCAACAACT 850 SSAN-DAS GTGAAGTTTATATCCTTACTAAAGAAGAAGGCGGACGTCACACTCCATTCTTCAACAACT 891 SMIT-NCTC12261 GTGAAGTTTACATCCTTACTAAAGAAGAAGGTGGACGTCACACTCCATTCTTCAACAACT 991 SPNE-R6 GTGAAGTCTACATCCTTACTAAAGAAGAAGGTGGACGTCACACTCCATTCTTCAACAACT 991 SPYO-M1GAS GTGAAGTATATATCCTTTCTAAAGACGAAGGTGGACGTCACACTCCATTCTTCAACAACT 991 35 SMUT-DAS GTGAAGTTTATATCCTTACTAAAGAAGAAGGTGGACGTCATACACCATTCTTCAATAACT 891 SMUT-UA15 9 GTGAAGTTTATATCCTTACTAAAGAGGAAGGTGGACGTCATACACCATTCTTCAATAACT 991 HINF-RdKW20 CAGAAGTGTACGTATTATCAAAAGATGAAGGTGGTCGTCATACTCCATTCTTCAAAGGTT 979 MCAT-DAS CAGAAGTATACGTGCTATCAAAAGAAGAAGGTGGTCGTCATACCCCATTCCTAAATGGCT 836 BPER-Tohamal CCGAGGTGTACATTCTGTCCAAGGAAGAGGGTGGCCGTCACACGCCGTTCTTCAACGGCT 985 40 BPAR-12822 CCGAGGTGTACATTCTGTCCAAGGAAGAGGGCGGCCGTCACACGCCGTTCTTCAACGGCT 985 BCEP2-DAS CCGAAGTGTACGTGCTGAGCAAGGACGAAGGCGGCCGTCACACGCCGTTCTTCAACAACT 869 BPSE-171Ob CTGAAGTGTACGTGCTGAGCAAGGACGAAGGCGGCCGCCACACGCCGTTCTTCAACAACT 985 SMAL-DAS GCGAAGTGTACGTCCTGTCGAAGGACGAAGGCGGCCGCCACACCCCGTTCTTCAACGGCT 890 PAER-PA01 GCGAAGTGTACGTGCTGTCCAAGGAAGAAGGTGGTCGTCACACCCCGTTCTTCAAGGGCT 988 45 KPNE-DAS CTGAAGTGTACATCCTGTCCAAAGACGAAGGCGGCCGTCATACTCCGTTCTTCAAAGGCT 863 MAVI-K10 GCCAGGTCTACATCCTGTCCAAGGACGAGGGCGGCCGGCACACGCCGTTCTTCAACAACT 985 MAVI-paratub GCCAGGTCTACATCCTGTCCAAGGACGAGGGCGGCCGGCACACGCCGTTCTTCAACAACT 985 MAISpig-DAS GCAGCGTCTACATCCTGTCCAAGGACGAGGGCGGCCGGCACACGCCGTTCTTCAACAACT 880 MKAN-DAS GCCAGGTTTACATCCTGTCCAAGGACGAGGGTGGCCGGCACACGCCGTTCTTCAACAACT 886 50 MTUB-H3 7Rv GCCAGGTCTACATCCTGTCCAAGGACGAGGGCGGCCGGCACACGCCGTTCTTCAACAACT 985 MTUB-CDC1551 GCCAGGTCTACATCCTGTCCAAGGACGAGGGCGGCCGGCACACGCCGTTCTTCAACAACT 985 MAVI-DAS GCAGCGTCTACATCCTGTCCAAGGACGAGGGCGGCCGCCACACGCCGTTCTTCAACAACT 826 NCTC13129 GCTCTGTCTACGTTCTGTCCAAGGACGAGGGTGGCCGCCACACCCCATTCTTCGACAACT 985 NMEN-MC58 CAGAAGTATACGTACTGAGCAAAGAAGAGGGTGGTCGTCACACTCCGTTCTTCGCCAACT 979 55 NMEN-Z2491 CAGAAGTATACGTACTGAGCAAAGAAGAGGGCGGCCGCCATACCCCGTTCTTCGCCAACT 979 NMEN-DAS CAGACGTGTACGTACTGAGCAAAGAAGAGGGCGGCCGCCATACTCCGTTCTTCGCCAACT 821 MPNE-HF2 ATAGACCACAATTCTACTTCAGAACTACTGATGTTACTGGACAAATCACACTTGATAAAG 1039 MPNE-M129 ACCGTCCCCAATTCTACTTCCGTACTACAGACGTTACTGGTTCGATTTCCCTACCAGAAA 1039 60 LPNE-Paris ACCGTCCACAATTCTATTTCAGAACCACTGACGTGACAGGTACTTGTGACTTGCCATCAG 1058 LPNE2-DAS ACCGTCCACAATTCTATTTCAGAACCACTGACGTAACA---------------------- 906 LPNE-Philadelphial ACCGTCCACAATTCTATTTCAGAACCACTGACGTGACAGGTACTTGTGACTTGCCATCAG 1045 LPNE-Lens ACCGTCCACAATTCTATTTCAGAACCACTGACGTGACAGGTACTTGTGACTTGCCATCAG 1045 LLON-DAS ATAGACCACAGTTTTATTTTAGAACAACAGACGTAACAGGAACTTGTGATTTACCATCTG 929 65 FNUC-DAS ACAGACCTCAATTCTATTTTAGAACTACTGATATCACTGGTGCAGTAACTTTACCAGATG 917 CPNE-CWLO29 ACAGACCTCAGTTCTTCTTCCGTACTACAGACGTGACAGGAGTCGTAACTCTTCCTGAAG 1039 EFAE -DAS ACCGTCCTCAATTCTACTTCCGTACAACAGACGTTACTGGTGTTGTAGAATTGCCAGAAG 919 EFAE-V583 ACCGTCCTCAATTCTACTTCCGTACAACAGACGTTACTGGTGTTGTAGAATTGCCAGAAG 1042 SAUR-MuS0 ATCGTCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTTCACTTACCAGAAG 1039 70 SAUR-N315 ATCGTCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTTCACTTACCAGAAG 1039 SAUR-MW2 ATCGTCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTTCACTTACCAGAAG 1039 SAUR-MSSA476 ATCGTCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTTCACTTACCAGAAG 1039 SAUR-MRSA252 ATCGTCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTTCACTTACCAGAAG 1039 WO 2007/012131 PCT/AU2006/001056 -33 SEPI-12228 ATCGCCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTAAACTTACCAGAAG 1039 SEPI-RPG2A ATCGCCCACAATTCTATTTCCGTACTACTGACGTAACTGGTGTTGTAAACTTACCAGAAG 1039 SMIT-DAS ACCGTCCACAGTTCTACTTCCGTACAACTGACGTAACTGGATCTATCGAACTTCCAGCTG 910 SSAN-DAS ACCGTCCACAGTTCTACTTCCGTACAACTGACGTTACAGGTTCAATCGAACTTCCAGCAG 951 5 SMIT-NCTC12261 ACCGTCCACAATTCTACTTCCGTACTACTGACGTTACAGGTTCAATCGAACTTCCAGCAG 1051 SPNE-R6 ACCGTCCACAATTCTACTTCCGTACTACTGACGTTACAGGTTCAATCGAACTTCCAGCAG 1051 SPYO-M1GAS ACCGTCCACAATTCTACTTCCGTACAACTGACGTAACAGGTTCAATCGAACTTCCAGCAG 1051 SMUT-DAS ATCGTCCACAATTCTACTTCCGTACAACTGACGTAACTGGTTCAATTGAGTTGCCAGCAG 951 SMUT-UA159 ATCGTCCACAATTCTACTTCCGTACAACTGACGTAACTGGTTCAATTGAGTTGCCAGCAG 1051 10 HINF-RdKW20 ACCGTCCACAATTCTATTTCCGTACAACAGACGTGACTGGTACAATCGAATTACCAGAAG 1039 MCAT-DAS ATCGTCCACAGTTCTACTTCCGTACCACAGACGTAACTGGTGCCATCACCCTACAAGAAG 896 BPER-TohamaI ATCGTCCGCAGTTCTACTTCCGCACGACGGACGTGACCGGCACGATCGACCTGCCGGCGG 1045 BPAR-12822 ATCGTCCGCAGTTCTACTTCCGCACGACGGACGTGACCGGCACGATCGACCTGCCGGCGG 1045 BCEP2-DAS ACCGTCCGCAGTT----------------------------------------------- 882 15 BPSE-1710b ACCGTCCGCAGTTCTACTTCCGTACGACGGACGTGACGGGCTCGATCGAGCTGCCGAAGG 1045 SMAL-DAS ACCGTCCGCAGTTCTACTTCCGCACCACCGACATCACCGGCGCAGCTGCGCTGCCGGAAG 950 PAER-PA01 ACCGTCCGCAGTTCTACTTCCGTACCACCGATGTGACCGGTAACTGCGAACTGCCGGAAG 1048 KPNE-DAS ACCGTCCGCAGTTCTACTTCCGTACTACTGACGTGACTGGCACCATCGAACTGCCGGAAG 923 MAVI-K10 ACCGCCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACGCTGCCGGAGG 1045 20 MAVI-paratub ACCGCCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACGCTGCCGGAGG 1045 MAISpig-DAS ACCGTCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACGCTGCCGGAGG 940 MKAN-DAS ACCGTCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACGCTGCCGGAGG 946 MTUB-H37Rv ACCGTCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACACTGCCGGAGG 1045 MTUB-CDC1551 ACCGTCCGCAGTTCTACTTCCGCACCACCGACGTGACCGGTGTGGTGACACTGCCGGAGG 1045 25 MAVI-DAS ACCGCCCGCAGTTCTACTTCCGTACCACGGACGTGACCGGCGTGGTGACCCTCCCCGAG- 885 NCTC13129 ACCGCCCACAGTTCTACTTCCGCACCACCGACGTTACCGGTGTTGTGAAGCTTCCTGAGG 1045 NMEN-MC58 ACCGTCCGCAATTCTACTTCCGTACCACCGACGTAACCGGCGCGGTTACTTTGGAAGAAG 1039 NMEN-Z2491 ACCGTCCCCAATTCTACTTCCGTACCACCGACGTAACCGGCGCGGTTACTTTGGAAGAAG 1039 NMEN-DAS ACCGTCCGCA-TTCTACTTCCGTACCACCGACGTAACCGGCGCGGTTACTTTGGAAGAAG 880 30 MPNE-HF2 GTGTTGAAATGATTAACCCAGGAGATAACACTAAGATTACTGTTGAACTTATTTCTCCAA 1099 MPNE-M129 ACACCGAAATGGTGCTACCAGGTGACAATACCTCGATTACAGTTGAACTAATTGCACCAA 1099 LPNE-Paris GAGTTGAAATGGTAATGCCTGGAGATAATGTGCAATTAGTTGTTAGCTTGCATGCTCCGA 1118 LPNE2-DAS ----------------------------------------------------------- 35 LPNE-Philadelphial GAGTTGAAATGGTAATGCCTGGAGATAATGTGCAATTAGTTGTTAGCTTGCATGCTCCGA 1105 LPNE-Lens GAGTTGAAATGGTAATGCCTGGAGATAATGTGCAATTAGTTGTTAGCTTGCATGCTCCGA 1105 LLON-DAS GAGTTGAAATGGTAATGCCTGGAGATAACGTACAGTTG- ---------------------- 967 FNUC-DAS GAGTAGAAATGGTTATGCCAG--------------------------------------- 938 CPNE-CWLO29 GAACTGAAATGGTAATGCCTGGAGATAACGTTGAGCTTGATGTTGAGCTCATTGGAACAG 1099 40 EFAE-DAS GTACTGAAATGGTAATGCCTGGTGATAACGT----------------------------- 950 EFAE-VS83 GTACTGAAATGGTAATGCCTGGTGATAACGTTGCTATGGACGT TGAATTAATTCACCCAA 1102 SAUR-Mu50 GTACTGAAATGGTAATGCCTGGTGATAACGTTGAAATGACAGTAGAATTAATCGCTCCAA 1099 SAUR-N315 GTACTGAAATGGTAATGCCTGGTGATAACGTTGAAATGACAGTAGAATTAATCGCTCCAA 1099 SAUR-MW2 GTACTGAAATGGTAATGCCTGGTGATAACGTTGAAATGACAGTAGAATTAATCGCTCCAA 1099 45 SAUR-MSSA476 GTACTGAAATGGTAATGCCTGGTGATAACGTTGAAATGACAGTAGAATTAATCGCTCCAA 1099 SAUR-MRSA252 GTACTGAAATGGTAATGCCTGGTGATAACGTTGAAATGACAGTAGAATTAATCGCTCCAA 1099 SEPI-12228 GTACAGAAATGGTTATGCCTGGCGACAACGTTGAAATGACAGTTGAATTAATCGCTCCAA 1099 SEPI-RP62A GTACAGAAATGGTTATGCCTGGCGACAACGTTGAAATGACAGTTGAATTAATCGCTCCAA 1099 SMIT-DAS GAACTGAAATGGTAATGCCTGGTGATAACGTGACTATCGACGTT ---------------- 954 50 SSAN-DAS GTACTGAAATGGTAATGCCTGGTGATAACGTAACAATCGACGTTGAGT ------------ 999 SMIT-NCTC12261 GTACTGAAATGGTAATGCCTGGTGATAACGTGACAATCGACGTTGAGTTGATCCACCCAA 1111 SPNE-R6 GTACTGAAATGGTAATGCCTGGTGATAACGTGACAATCGACGTTGAGTTGATTCACCCAA 1111 SPYO-M1GAS GTACAGAAATGGTTATGCCTGGTGATAACGTGACAATCAACGTTGAGTTGATCCACCCAA 1111 SMUT-DAS GTACTGAAATGGTTATGCCTGGTGATA--------------------------------- 978 55 SMUT-UA159 GTACTGAAATGGTTATGCCTGGTGATAACGTTACTATTGACGTTGAATTGATCCATCCAA 1111 HINF-RdKW20 GCGTGGAAATGGTAATGCCAGGCGATAACATCAAGATGACAGTAAGCTTAATCCACCCAA 1099 MCAT-DAS GCACTGAAATGGTTATGCCAGGTGATAACGTTGAGATGAGCGTTGAGCTAATC-ACCCAA 955 BPER-TohamaI ACAAGGAAATGGTGCTGCCGGGCGACAACGTGTCGATGACCGTCAAGCTGCTGGCCCCGA 1105 BPAR-12822 ACAAGGAAATGGTGCTGCCGGGCGACAACGTGTCGATGACCGTCAAGCTGCTGGCCCCGA 1105 60 BCEP2-DAS ----------------------------------------------------------- BPSE-1710b ACAAGGAAATGGTGATGCCGGGCGACAACGTGTCGATCACGGTGAAGCTGATCGCGCCGA 1105 SMAL-DAS GCGTCGAAATGGTGATGCCGGGTGACAACGTCAAGATGGTCGTCAC -------------- 996 PAER-PA01 GCGTAGAGATGGTAATGCCGGGCGACAACATCAAGATGGTTGTCACCCTGATCGCTCCGA 1108 KPNE-DAS GCGTAGAGATGGTAATGCCGGGCGACAACATCAAAATGG- ----------------------- 962 65 MAVI-K10 GCACCGAGATGGTGATGCCCGGTGACAACACCAACATCTCGGTGAAGCTGATCCAGCCCG 1105 MAVI-paratub GCACCGAGATGGTGATGCCCGGTGACAACACCAACATCTCGGTGAAGCTGATCCAGCCCG 1105 MAISpig-DAs GCACCGAAATGGTGATGCCCGGTGACAACACCAACATCTCGGTCAAGCTGATCCAGC --- 997 MKAN-DAS GCACCGAGATGGTGATGCCCGGTGACA--------------------------------- 973 MTUB-H37Rv GCACCGAGATGGTGATGCCCGGTGACAACACCAACATCTCGGTGAAGTTGATCCAGCCCG 1105 70 MTUB-CDC1551 GCACCGAGATGGTGATGCCCGGTGACAACACCAACATCTCGGTGAAGTTGATCCAGCCCG 1105 MAVI-DAS ----------------------------------------------------------- NCTC13129 GCACCGAGATGGTCATGCCTGGCGACAACGTCGACATGTCCGTCACCCTGATCCAGCCTG 1105 NMEN-MC58 GTGTAGAAATGGTAATGCCGGGTGAAAACGTAACCATCACCGTAGAACTGATTGCGCCTA 1099 WO 2007/012131 PCT/AU2006/001056 -34 NMEN-Z2491 GTGTGGAAATGGTAATGCCGGGCGAGAACGTAACCATCACCGTAGAACTGATTGCGCCTA 1099 NMEN-DAS GAGTGGAAATGGTAATGCCTGGTGAGAACGTAACCATCACCGTAGA-CTGATTGCGTCTA 939 MPNE-HF2 TTGCTGTTGAAGAAGGAAGTAAATTCTCAATCCG-TGAAGGTGGAAGAACAGTAGGTGCT 1158 5 MPNE-M129 TTGCTTGTGAAAAAGGTAGTAAGTTCTCCATCCG-TGAAGGTGGTCGAACGGTTGGTGCT 1158 LPNE-Paris TTGCGATGGATGAAGGTTTAAGATTCGCAATTAG-AGAGGGTGGCCGAACTGTTGGCGCC 1177 LPNE2-DAS ----------------------------------------------------------- LPNE-Philadelphial TTGCGATGGATGAAGGTTTAAGATTCGCAATTAG-AGAGGGTGGCCGAACTGTTGGCGCC 1164 LPNE-Lens TTGCGATGGATGAGGGTTTAAGATTCGCAATTAG-AGAGGGTGGCCGAACTGTTGGCGCC 1164 10 LLON-DAS ----------------------------------------------------------- FNUC-DAS ----------------------------------------------------------- CPNE-CWL02 9 TTGCTCTTGAAGAAGGAATGAGATTTGCAATTCG-TGAAGGTGGTCGTACTATCGGCGCT 1158 EFAE-DAS ----------------------------------------------------------- EFAE-Vs83 TCGCTATCGAAGACGGAACTCGTTTCTCTATTCG-TGAAGGCGGACGTACTGTAGGTTCA 1161 15 SAUR-Mu5o TCGCGATTGAAGACGGTACTCGTTTCTCAATCCG-CGAAGGTGGACGTACTGTAGGATCA 1158 SAUR-N315 TCGCGATTGAAGACGGTACTCGTTTCTCAATCCG-CGAAGGTGGACGTACTGTAGGATCA 1158 SAUR-MW2 TCGCGATTGAAGACGGTACTCGTTTCTCAATCCG-TGAAGGTGGACGTACTGTAGGATCA 1158 SAUR-MSSA476 TCGCGATTGAAGACGGTACTCGTTTCTCAATCCG-TGAAGGTGGACGTACTGTAGGATCA 1158 SAUR-MRSA252 TCGCGATTGAAGACGGTACTCGTTTCTCAATCCG-TGAAGGTGGACGTACTGTAGGATCA 1158 20 SEPI-12228 TCGCTATCGAAGACGGAACTCGTTTCTCAATTCG-TGAAGGTGGACGTACTGTTGGATCA 1158 SEPI-RP62A TCGCTATCGAAGACGGAACTCGTTTCTCAATTCG-TGAAGGTGGACGTACTGTTGGATCA 1158 SMIT-DAS ----------------------------------------------------------- SSAN-DAS ----------------------------------------------------------- SMIT-NCTC12261 TCGCCGTAGAACAAGGTACTACATTCTCTATCCG-TGAGGGTGGACGTACTGTTGGTTCA 1170 25 SPNE-R6 TCGCCGTAGAACAAGGTACTACATTCTCTATCCG-TGAGGGTGGACGTACTGTTGGTTCA 1170 SPYO-M1GAS TCGCCGTAGAACAAGGTACTACTTTCTCAATCCG-TGAAGGTGGACGTACTGTTGGTTCA 1170 SMUT-DAS ----------------------------------------------------------- SMUT-UA159 TCGCTGTTGAACAAGGTACTACTTTCTCTATTCG-TGAAGGTGGACGTACTGTTGGTTCT 1170 HINF-RdKW20 TTGCGATGGATCAAGGTTTACGTTTCGCAATCCG-TGAAGGTGGCCGTACAGTAGGTGCA 1158 30 MCAT-DAS TCGCATGGACA------------------------------------------------- 966 BPER-TohamaI TCGCCATGGAAGAAGGTCTGCGTTTCGCCATCCG-TGAAGGCGGTCGTACCGTCGGCGCC 1164 BPAR-12822 TCGCCATGGAAGAAGGTCTGCGTTTCGCCATCCG-TGAAGGCGGTCGTACCGTCGGCGCC 1164 BCEP2-DAS ----------------------------------------------------------- BPSE-1710b TCGCGATGGAAGAAGGTCTGCGCTTCGCGATCCG-CGAAGGCGGTCGCACCGTCGGCGCC 1164 35 SMAL-DAS ----------------------------------------------------------- PAER-PA01 TCGCCATGGAAGATGGCCTGCGCTTCGCGATCCG-CGAAGGCGGCCGTACCGTTGGCGCC 1167 KPNE-DAS ----------------------------------------------------------- MAVI-K10 TCGCCATGGACGAGGGTCTGCGGTTCGCCATCCG-CGAGGGTGGTCGCACCGTCGGCGCC 1164 MAVI-paratub TCGCCATGGACGAGGGTCTGCGGTTCGCCATCCG-CGAGGGTGGTCGCACCGTCGGCGCC 1164 40 MAISpig-DAS ----------------------------------------------------------- MK-AN-DAS ----------------------------------------------------------- MTUB-H37Rv TCGCCATGGACGAAGGTCTGCGTTTCGCGATCCG-CGAGGGTGGCCGCACCGTGGGCGCC 1164 MTUB-CDC1551 TCGCCATGGACGAAGGTCTGCGTTTCGCGATCCG-CGAGGGTGGCCGCACCGTGGGCGCC 1164 MAVI-DAS ----------------------------------------------------------- 45 NCTC13129 TCGCTATGGATGAGGGCCTGCGCTTCGCTATCCG- CGAGGGCTCCCGCACCGTCGGCGCT 1164 NMEN-MC58 TCGCTATGGAAGAAGGCCTGCGCTTTGCGATTCG-CGAAGGCGGCCGTACCGTGGGTGCC 1158 NMEN-Z2491 TCGCTATGGAAGAAGGTTTGCGCTTTGCGATTCG-CGAAGGCGGCCGTACCGTGGGTGCC 1158 NMEN-DAS TCGCTATGGAAGAG---CTGCGCTT-GCGTCGTGTCGCGCGTGTCCAT-------------- 983 50 MPNE-HF2 GGTACAGTAACTAAAGTTATTAAGTAA 1185 MPNE-M129 GGTTCAGTCACGGAAGTGCTTGAATAG 1185 LPNE-Paris GGTGTAGTCGCTAAAATAATCGAGTAA 1204 LPNE2-DAS -------------------------- LPNE -Philadelphial GGTGTAGTCGCTAAAATAATCGAGTAA 1191 55 LPNE-Lens GGTGTAGTCGCTAAAATAATCGAGTAA 1191 LLON-DAS -------------------------- FNUC-DAS -------------------------- CPNE-CWL029 GGAACGATTTCAAAGATCAATGCTTAA 1185 EFAE-DAS -------------------------- 60 EFAE-V583 GGCGTTGTTACTGAAATCGTTAAATAA 1188 SAUR-MuS0 GGCGTTGTTACTGAAATCATTAAATAA 1185 SAUR-N315 GGCGTTGTTACTGAAATCATTAAATAA 1185 SAUR-MW2 GGCGTTGTTACTGAAATCATTAAATAA 1185 SAUR-MSSA476 GGCGTTGTTACTGAAATCATTAAATAA 1185 65 SAUR-MRSA252 GGCGTTGTTACTGAAATCATTAAATAA 1185 SEPI-12228 GGCGTTGTAACTGAAATCTTTGAATAA 1185 SEPI-RP62A GGCGTTGTAACTGAAATCTTTGAATAA 1185 SMIT-DAS -------------------------- SSAN-DAS -------------------------- 70 SMIT-NCTC12261 GGTATGGTTACAGAAATCGAAGCTTAA 1197 SPNE-R6 GGTATGGTTACAGAAATCGAAGCTTAA 1197 SPYO-M1GAS GGTATCGTTTCAGAAATCGAAGCTTAA 1197 SMUT-DAS --------------------------- WO 2007/012131 PCT/AU2006/001056 - 35 SMUT -UA159 GGTATCGTTTCAGAAATCGAAGCTTAA 1197 HINF-RdKW20 GGCGTTGTTGCGAAAATCATCAAATAA 1185 MCAT-DAS -------------------------- BPER-Tohamal GGCGTCGTCGCCAAGATCATCAAGTAA 1191 5 BPAR-12822 GGCGTCGTCGCTAAGATCATCAAGTAA 1191 BCEP2-DAS -------------------------- BPSE-1710b GGCGTCGTCGCCAAGATCATCGAGTAA 1191 SMAL-DAS -------------------------- PAER-PA01 GGCGTGGTTGCCAAGATCATCGAGTAA 1194 10 KPNE-DAS -------------------------- MAVI-KI0 GGCCGGGTCGTCAAGATCATCAAGTAG 1191 MAVI-paratub GGCCGGGTCGTCAAGATCATCAAGTAG 1191 MAISpig-DAS -------------------------- MKAN-DAS ------------------------- 15 MTUB-H37RV GGCCGGGTCACCAAGATCATCAAGTAG 1191 MTUB-CDC1551 GGCCGGGTCACCAAGATCATCAAGTAG 1191 MAVI-DAS -------------------------- NCTC13129 GGTCGCGTTACCAAGATCATCAAGTAA 1191 NMEN-MC58 GGCGTGGTTTCTTCTGTTATCGCTTAA 1185 20 NMEN-Z2491 GGCGTGGTTTCTTCTGTTATCGCTTAA 1185 NMEN-DAS -------------------------- Abbreviations used in Table 1 MPNE - Mycoplasma pneumoniae 25 LPNE - Legionella pneunophila LLON - Legionella longbeachiae FNUC - Fusobacterium nucleatum CPNE - Chlamydophila pneumoniae EFAE - Enterococcus faecalis 30 SAUR - Staphylococcus aureus SEPI - Staphylococcus epidermidis SMIT - Streptococcus mitis SSAN - Streptococcus sanguis SPNE - Streptococcus pneumoniae 35 SPYo - Streptococcus pyogenes SMUT - Streptococcus mutans HINF - Haemophilus influenzae MCAT - Moraxella catarrhalis BPER - Bordetella pertussis 40 BPAR - Bordetella parapertussis BCEP - Burkholderia cepacia BPSE - Burkholderia pseudomallei SMAL - Stenotrophomonas maltophilia PAER - Pseudomonas aeruginosa 45 KPNE - Klebsiella pneumoniae MAVI - Mycobacterium avium MAIS - Mycobacterium intracellulare MKAN - Mycobacterium kansasii MTUB - Mycobacterium tuberculosis 50 CDIP - Corynebacterium diphtheriae NMEN - Neisseria meningitidis WO 2007/012131 PCT/AU2006/001056 -36 bacteria, intestinal flora, monerans, monerons, microbes, pathogens, pilus, protists, protistans, protoctists, viruses, rickettsieae, protozoans, algae spirillum and fungi. 5 In some embodiments, the target micro-organism is a prokaryotic micro-organism. Examples of prokaryotic micro organisms include Bordotella pertussis, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, 10 Staphylococcus aureus, Myobacterium tuberculosis, Escherichia coli, Streptococcus pyogenes, Burkholderia cepacia, Corynebacterium, Chlamydophila pneumoniae, Enterococcus faecalis, Fusobacterium nucleatum, Klebsiella pneumoniae, Legionella longbeachiae, Moraxella 15 catarrhalis, Neisseria meningitidis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus mutans, Streptococcus sanguis, and Serratia marcescens. 20 As shown in Table 2, the bacteria referred to above display a range of characteristics.

WO 2007/012131 PCT/AU2006/001056 -37 TABLE 2 Gram positive bacterial Gram negative bacterial species species Aerobic bacilli Aerobic bacilli Corynebacterium diphtheriae Bordetella pertussis Chlamydophila pneumoniae Haemophilus influenzae Serratia marcescens Moraxella catarrhalis Legionella pneumophila Legionella longbeachiae Mycoplasma pneumoniae Klebsiella pneumoniae Burkholderia cepacia Stenotrophomonas mal tophilia Pseudomonas aeruginosa Aerobic cocci Aerobic cocci Staphylocuccus aureus Neisseria meningitidis Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus pyogenes Streptpcoccus mutans Streptococcus sanguis Enterococcus faecalis Anaerobic bacilli Fusobacterium nucleatum Mycobacterium tuberculosis WO 2007/012131 PCT/AU2006/001056 -38 The methods of the invention for identifying micro organisms may be used in a variety of fields including, but not limited to, human medicine, epidemiology, drug development, veterinary medicine, agriculture, the 5 environment, food science, and industrial microbiology. For example, micro-organism identification may be used to determine the identity of a micro-organism found in a patient suffering from an infectious disease. Micro organism identification may also be used to monitor food 10 safety by testing for pathogens. Similarly, plants may be checked to determine if they harbour phytopathogenic bacteria. Further, the methods of the present invention may be used to identify drug resistant bacteria including antibiotic resistant strains of bacteria. 15 One method of the present invention for identifying a target microorgansim in a test sample comprises contacting the test sample or a product of the amplification process described supra, with a probe derived from the tuf gene 20 variable region for a time and under conditions sufficient for hybridization to take place. The term "probe" as used herein is interchangeably used with the terms "oligonucleotide probe" or "hybridization 25 probe" and refers to a short span of contiguous nucleotides, preferably between 10 and 50 nucleotides, that are complementary to at least a part of a tuf gene variable region from target microorganism, such that it is capable of specifically binding to a polynucleic acid as 30 defined herein from the target microorganism. The design, use and labelling of probes is described in Keller et al., DNA Probes, pp.149-213 (Stockton Press, 1989). The terms "specific binding" or "specifically binding" 35 refers to that interaction between a probe of the present invention and the corresponding polynucleic acid from a target microorganism.

WO 2007/012131 PCT/AU2006/001056 -39 As used herein the term "contacting" means to bring the test sample or amplification product into physical proximity with a probe derived from the tuf gene variable 5 region such that, if other conditions are suitable, hybridization can take place. The contacting may be direct or indirect. For example, the test sample may directly contact the probe such that hybridisation can take place. Alternatively, the sample may hybridise with 10 another molecule (eg another nucleic acid molecule) which in turn hybridises with the probe derived from a tuf gene variable region. "Hybridisation" is used herein to denote the pairing of 15 complementary nucleotide sequences to produce a DNA-DNA hybrid or a DNA-RNA hybrid. Complementary base sequences are those sequences that are related by the base pairing rules. In DNA, A pairs with T and C pairs with G. In RNA U pairs with A and C pairs with G. In this regard, the 20 terms "match" and "mismatch" as used herein refer to the hybridisation potential of paired nucleotides in complementary nucleic acid strands. Matched nucleotides hybridise efficiently, such as the classical A-T and G-C pair mentioned above. Mismatches are combinations of 25 nucleotides that do not hybridise efficiently. Defining appropriate hybridisation conditions is within the skill of the art. See eg., Sambrook et al., supra. However, ordinarily, "stringent conditions" for 30 hybridisation or annealing of probes are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015M NaCl/0.0015M sodium citrate/0.1% sodium dodecyl sulfate (SDS) at 50 0 C, or 35 (2) employ during hybridisation a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% WO 2007/012131 PCT/AU2006/001056 -40 polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750mM NaCl, 75mM sodium citrate at 42 0 C. An example of medium stringency conditions for 5 hybridisation is the use of 50% formamide, 5 X SSC (0.75M NaCl, 0.075M sodium citrate), 50mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 X Denhardt's solution, sonicated salmon sperm DNA (50 pag/mL), 0.1% SDS, and 10% dextran sulfate at 42 0 C, with washes at 42 0 C in 0.2 X SSC 10 and 0.1% SDS. Suitable hybridisation and washing conditions depend on specific applications. The higher the degree of similarity between two micro-organisms that need to be 15 differentiated, the higher the stringency of hybridisation and washing conditions should be. For example, when an application requires differentiating micro-organisms on the genus level, hybridisation and washing conditions of relatively low stringency may be all that is necessary. 20 However, when differentiating between micro-organisms on the species level, wherein the micro-organism share a higher degree of similarity, hybridisation and washing conditions of higher stringency are required. Further, when differentiating between micro-organisms on the strain 25 level wherein the micro-organisms share an even higher degree of similarity, hybridisation and washing conditions of even higher stringency are required. In some embodiments, the step of contacting the test 30 sample comprises hybridization with at least a portion of a tuf gene variable region with a set of probes comprising at least one probe selected from the group consisting of SEQ ID NOs:12 to 57, 208 to 209 and 210. 35 In other embodiments, the at least one probe is selected from the group consisting of SEQ ID NOs:12 to 79, 208 to 209 and 210. In other embodiments, the at least one probe WO 2007/012131 PCT/AU2006/001056 -41 is selected from the group consisting of SEQ ID NOs:12 to 392 and 393. In some embodiments, the target microorganism is selected 5 from the group consisting of Bordetella species, Chlamydophila species, Haemophilus species, Legionella species, Mycoplasma species, Mycobacterium species, Staphylococcus species, Streptococcus species, Pseudomonas species, Moraxella 10 species and Fusobacterium species, Stenotrophomonas species, Burkholderi species, Enterococcus species, Corynebacterium species and Neisseria species, wherein the probe is selected from the group consisting of: 15 for Haemophilus influenzae: TATTATCCGTACAGGTGATGAAGTAGAAA (SEQ ID NO. :12); AAAGATACAGCGAAAACTACTGTAACG (SEQ ID NO. :13); CATCGGTGCATTATTACGTGGTAC (SEQ ID NO. :14); 20 CATACTCCATTCTTCAAAGGTTACCG (SEQ ID NO. :15); TGACTGGTACAATCGAATTACCAGAA (SEQ ID NO. : 16); CCGTAAATTACTTGACGAAGGTCG (SEQ ID NO. :17); ACTTCGAATC AGAAGTGTAC (SEQ ID NO. :64); CAAACGTGAA GAAATCGAAC (SEQ ID NO. :65); 25 CGATAACATC AAGATGACAG T (SEQ ID NO. :66); for Moraxella catarrhalis: TGAGCGTGACATCGATAAGTCA (SEQ ID NO. :18); 30 CAGGCATTATTAAAGTTGGTGATGAAATT (SEQ ID NO. :19); AAACCAACTACTAAAACCACTTGTACTG (SEQ ID NO. :20); CGTAAGCTGCTAGACGAAGGT (SEQ ID NO. :21); TACCCCATTCCTAAATGGCTATCG (SEQ ID NO. :22); TAACTGGTGCCATCACCCTAC (SEQ ID NO. :23); 35 AGTTTGATGCAGAAGTATACG (SEQ ID NO.:208) TATCCTACTACGTGGTACTAA (SEQ ID NO.:209) ATAACGTTGAGATGAGCG (SEQ ID NO. :210) WO 2007/012131 PCT/AU2006/001056 -42 for Enterococcus faecalis: AAGGCGACGAGTCTTATGAAGA (SEQ ID NO. :24); 5 AATTAATGGCTGCAGTTGACGAAT (SEQ ID NO. :25); GAAGTTCGCGTTGGTGACG (SEQ ID NO. :26); GACGAAACATCTAAAACAACTGTTACAG (SEQ ID NO. :27); TGGTGTTGTAGAATTGCCAGAAG (SEQ ID NO. :28); TAAACCAGCTACAATCACTCCACA (SEQ ID NO. :29); 10 for Staphylococcus aureus: GTTGACATGGTTGACGATGAAGAATTA (SEQ ID NO.:30); CTTAGAATTAATGGAAGCTGTAGATACTTACA (SEQ ID NO. :31); 15 ATCATCGGTTTACATGACACATCTAAAA (SEQ ID NO. :32); CACCACATACTGAATTTAAAGCAGAAGTA (SEQ ID NO. :33); CATTCTTCTCAAACTATCGTCCACAA (SEQ ID NO. :34); CTGGTGTTGTTCACTTACCAGAAG (SEQ ID NO. :35); TACTGAAATGGTAATGCCTGGTGATA (SEQ ID NO. :36); 20 CCAATCGCGATTGAAGACGG (SEQ ID NO. :37); CTGGTTCAGCATTAAAAGCTTTAGAAG (SEQ ID NO. :38); TGACAACATTGGTGCATTATTACGT (SEQ ID NO.:39); TGTTACAGGTGTTGAAATGTTCCG (SEQ ID NO.:40); GTATTATCAAAAGACGAAGGTGGACG (SEQ ID NO. :41); 25 GCGATGCTCAATACGAAGAAAAAATC (SEQ ID NO. :42); TGAATTCAAA GCAGAAGTAT AC (SEQ ID NO. :76); ATTATTACGT GGTGTTGCTC (SEQ ID NO.:77); GTGATAACGT TGAAATGACA G (SEQ ID NO. :78); 30 for Staphylococcus epidermidis: TAGACTTAATGCAAGCAGTTGATGATTAC (SEQ ID NO. :43); CCACACACAAAATTCAAAGCTGAAG (SEQ ID NO. :44); CTGGTGTTGTAAACTTACCAGAAGG (SEQ ID NO. :45); 35 GAAATGGTTATGCCTGGCGAC (SEQ ID NO.:46); CTGGTTCTGCATTAAAAGCATTAGAAG (SEQ ID NO. :47); TGACAACATCGGTGCTTTATTACG (SEQ ID NO. :48); WO 2007/012131 PCT/AU2006/001056 -43 CTGTTACTGGTGTAGAAATGTTCCG (SEQ ID NO. :49); CGTATTATCTAAAGATGAAGGTGGACG (SEQ ID NO. :50); for Pseudomonas aeruginosa: 5 AAGTTCGAGTGCGAAGT (SEQ ID NO. :51); AAGGCGTAGAGATGGTAAT (SEQ ID NO. :52); TTCTTCAAGGGCTACCG (SEQ ID NO. :53); ATCATCAAGGTCCAGGAAGAAGT (SEQ ID NO. :54); 10 ACCAAGACTACCTGCACCG (SEQ ID NO. :55); TGTACGTGCTGTCCAAGGAA (SEQ ID NO. :56); CCGGTAACTGCGAACTGC (SEQ ID NO. :57); CACGTTGACTGCCCCGGTCACGC (SEQ ID NO. :85); ACGCCTTCCGGCAGTTCGCAGTTAC (SEQ ID NO. :86); 15 ATCGGTCACGTTGACCATGGCA (SEQ ID NO. :87); GCCGCCTTCGCGGATCGCGAA (SEQ ID NO. :88); for Bordetella pertussis: 20 GTACATTCTG TCCAAGGAAG (SEQ ID NO. :58); GACAACGTGG GTATCTTG (SEQ ID NO. :59); GACAAGGAAA TGGTGCT (SEQ ID NO.:60); for Chlamydophila pneumoniae: 25 AATTTAAGTC AGCTGTTTAC G (SEQ ID NO. :61); GAGGTATTGG AAAGAACGAT (SEQ ID NO.:62); ATAACGTTGA GCTTGATGTT (SEQ ID NO. :63); 30 for Legionella pneumophila: AGTTTGAAGC AGAAGTGTAT (SEQ ID NO. :67); TGTTATTACG AGGTACGAAG (SEQ ID NO. :68); AGATAATGTG CAATTAGTTG TTA (SEQ ID NO.:69); 35 for Mycoplasma pneumoniae: WO 2007/012131 PCT/AU2006/001056 -44 GAAATTTAAA GCGGAAATCT ATG (SEQ ID NO. :70); GAACGTGGTC AAGTGTTAG (SEQ ID NO.:71); GACAATACCT CGATTACAGT (SEQ ID NO. :72); 5 for Mycobacterium tuberculosis AACATCTCGG TGAAGTTGAT (SEQ ID NO. :73); TGACAACACC AACATCTC (SEQ ID NO. :74); ACGAAGGTCT GCGTTT (SEQ ID NO.:75); 10 for Streptococcus pneumoniae AATTCAAAGG TGAAGTCTAC A (SEQ ID NO. :79); CAACGTGATG AAATCGAAC (SEQ ID NO. :80); GACAATCGAC GTTGAGTT (SEQ ID NO.:81); 15 for Streptococcus pyogenes CAAAGGTGAA GTATATATCC TTTC (SEQ ID NO. :82); CAACGTGACG AAATCGAA (SEQ ID NO. :83); 20 CGTGACAATC AACGTTGA (SEQ ID NO. :84); and combinations thereof. Once hybridization is believed to have taken place then 25 any hybrids formed are detected. The person skilled in the art would be readily able to detect hybridisation between the probes of the invention and the polynucleic acid of the invention. For example, where neither the polynucleic acid or probe is labelled, hybridisation can be detected 30 using a DNA intercalating dye such as ethidium bromide, SYBR*Green (Applied Biosystems, Scoresby VIC, Australia), or SYTOX Orange (Invitrogen, Mount Waverley VIC, Australia). These dyes bind efficiently to double stranded DNA. Therefore when hybrids between the target polynucleic 35 acid and the probe nucleotide sequence are formed, staining with a dye as described above will facilitate detection of the resulting hybrids.

WO 2007/012131 PCT/AU2006/001056 -45 In some preferred embodiments of the present invention, a polynucleic acid derived from a test sample or a probe is labelled to facilitate hybridisation detection. Methods 5 and materials that can be used to label DNA or RNA molecules are known in the art. In the examples below, a method of labelling the DNA with Cy3 or Cy5 is described. However, other known labelling materials and methods may also be used. For example, other Cy dyes such as Cy3.5 10 and Cy5.5, Alexa fluorescent dyes and radioactive isotopes such as 32 P and 35S and the like can also be used to label the whole genomic DNA to facilitate the detectiQn of hybridisation. Furthermore, a two-colour fluorescent labelling strategy may be used in the present invention. 15 The strategy is described in Ramsay, 1998, Nat. Biotech., 16:40-44) and Shalon et al., 1996, Genome Res., 6:639-645, both of which are incorporated by reference in their entirety. Such multiple-colour hybridisation detection strategy minimises variations resulting from inconsistent 20 experimental conditions and allows direct and quantitative comparison of target abundance among different samples (see Ramsay, 1998, supra and Shalon et al., 1996, supra). The label is one that preferably does not provide a variable signal, but instead provides a constant and 25 reproducible signal over a given period of time. In some embodiments, the preferred method of contacting probes and test samples and detecting microorganisms is by using a microarray. A "microarray" is typically a 2 30 dimensional array upon which two or more probes of the invention have been deposited. In some embodiments there are at least 3 positions on the microarray containing a probe each having a different sequence of the invention. This has the advantage of minimising false positives. 35 Another method of detecting the presence of polynucleic acid from target microorganisms is specific nucleic acid WO 2007/012131 PCT/AU2006/001056 -46 microarrays and microchip technology. A microarray is a tool for detecting gene or nucleic acid sequence presence and typically consists of a small membrane or glass slide onto which samples of many probes have been arranged in a 5 regular pattern. For example, oligonucleotide probes for microorganism polynucleic acid disclosed herein can be deposited at predetermined locations on a glass slide. Test samples or 10 polynucleic acid isolated therefrom can be added to the probes under conditions which allow hybridization or binding between the probes and polynucleic acid if present in the test sample. Alternatively, polynucleic acid from a test sample may be applied to the slide before adding 15 probes for polynucleic acid disclosed herein. Binding between the probes and polynucleic acid can be detected by any means known in the art and specific binding between the polynucleic acid and a probe indicates the polynucleic acid is present in the test sample. 20 The methodology of hybridisation of polynucleic acids and microarray technology is well known in the art. For example, the specific preparation of polynucleic acids for hybridisation and probes, slides, and hybridisation 25 conditions are provided in PCT/USO1/10482, herein incorporated by reference. Microarray technology allows for the measurement of thousands of genes or polynucleic acids simultaneously 30 thereby presenting a powerful tool for identifying the presence of microorganisms. Two microarray technologies are currently in wide use. The first are cDNA arrays and the second are oligonucleotide arrays. Although differences exist in the construction of these chips, 35 essentially all downstream data analysis and output are the same. The product of these analyses are typically measurements of the intensity of the signal received from WO 2007/012131 PCT/AU2006/001056 -47 a labelled probe used to detect a polynucleic acid from the test sample that hybridizes to a polynucleic acid at a known location on the microarray. Typically, the signal intensity is proportional to the polynucleic acid 5 quantity. A large number of such techniques are available and useful. Preferred methods can be found in US Pat. Nos. 6,271,002 to Linsley et al.; US Pat. No. 6,218,122 to Friend et al.; US Pat. No. 6,218,114 to Peck et al.; and US Pat. No. 6,004,755 to Wang et al., the disclosure of 10 each of which is incorporated herein by reference. In a preferred method, biotinylated probes are prepared and hybridized to a microarray such as Affymetrix HG-U133A oligonucleotide microarrays (Affymetrix, Santa Clara, CA) 15 by methods such as those described in Hoffmann et al., 2005, Mol Biotechnol., 29:31-8. Array images can then be reduced to intensity values for each probe (CEL files) using, for example, Affymetrix MAS 5.0 software. Expression measures are extracted using robust multi-array 20 analysis (RMA) for example as described in Irizarry et al., 2003, Nucleic Acids Res., 31:e15 and Dallas et al., 2005, BMC Genomics., 6:59. Once a microorganism(s) has been detected using the 25 invention described herein, an appropriate diagnosis, prognosis or treatment might be effected. Accordingly, the invention further provides a method for the prognosis, diagnosis, prevention, or treatment in a subject of a disease, comprising the detection of hybridisation between 30 a polynucleic acid in a test sample and a probe derived from a tuf gene variable region. Detecting hybridisation between a nucleic acid molecule in a sample and variable region of a gene enables identification of a micro organism in the sample. This information can be used to 35 determine whether the disease is caused by a pathogenic micro-organism, and hence the prognosis, diagnosis, prevention, or treatment for the disease.

WO 2007/012131 PCT/AU2006/001056 -48 As used herein "prognosis" means a prediction of the course and outcome of a disease or the likelihood of a subject developing a disease. 5 As used herein "diagnosis" means the process of identifying a disease, such as by its symptoms, laboratory tests (including genotypic tests), and physical findings. 10 As used herein "prevention" means any prevention of a disease in a subject and includes preventing the disease from occurring in a subject that may be predisposed to the disease, but has not yet been diagnosed as having it. The effect may be prophylactic in terms of completely or 15 partially preventing the disease or sign or symptom thereof. As used herein "treatment" or "treating" means any treatment of a disease in a subject by administering a 20 medicament to the subject following the detection of a particular microorganism. "Treatment" and "treating" includes: (a) inhibiting the disease, i.e., arresting its development; or (b) relieving or ameliorating the symptoms of the disease, i.e., cause regression of the symptoms of 25 the disease. The effect may be therapeutic in terms of a partial or complete cure of the disease. Methods of the invention can be used in the prognosis, diagnosis, prevention, or treatment of any subject, such 30 as an animal or plant, as all animals and plants are infected by micro-organisms and are subject to diseases and disorders caused by micro-organisms. As used herein an "animal" means any animal, such as a 35 human or a mammal of economical importance and/or social importance to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and WO 2007/012131 PCT/AU2006/001056 -49 wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also provided is the treatment of birds, including the treatment of those kinds of birds that are endangered, 5 kept in zoos, as well as fowl, and more particularly domesticated fowl, eg., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, provided is the treatment of livestock, including, but not 10 limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like. The term does not denote a particular age. Thus, both adult and newborn subjects are intended to be covered. 15 As used herein a "plant" includes any member of the plant kingdom including, but not limited to, eukaryotic algae, mosses, club mosses, ferns, angiosperms, gymnosperms, and lichens (which contain algae) including any parts (eg pollen, seeds, cells, tubers, stems) thereof, and any 20 cellular components (eg plasmids, ribosomes, etc.) thereof. "Disease" as used herein is a general term used to refer to any departure from health in which a subject suffers. 25 In some embodiments the disease is one associated with pathogens (including animal pathogens) and in particular infectious diseases, respiratory infections, including, pneumonia (including community acquired pneumonia), 30 whooping cough, meningitis, typhus, tuberculosis, diptheria, typhoid fever and bacterial diarrhoea; gastrointestinal tract infections, including gastroenteritis; dermal infections; genital tract infections; urinary tract infections; nosocomial 35 infections; typhoid fever; botulism; strep throat; rheumatic fever; syphilis, cystitis; kidney infection; folliculitis; furunculosis (boils); impetigo (school WO 2007/012131 PCT/AU2006/001056 -50 sore); methicillin resistant Staphylococcus aureus; staphylococcal scalded skin syndrome; toxic shock syndrome; cellulitis, erysipelas; necrotising fascilitis; scarlet fever; wound infections ie. dermatitis and 5 scabies. A medical or veterinary practitioner, after being provided with the results of the above method may prescribe appropriate treatment according to his or her knowledge 10 and skill. However, in an alternative embodiment, a computer software program may be provided to advise on the appropriate treatment of the patient, once the identification of the micro-organism has taken place. 15 Embodiments of the present invention may also be conveniently provided in kits. The kits of the invention may comprise reagents such as probes or primers, reference polynucleic acids, buffers, enzymes and the like. The kits of the invention may also comprise instructions for 20 carrying out the methods of the present invention. Such instructions may take the form of package inserts, or labels, or referrals to other sources such as books, journals, websites, and compact discs. 25 The invention will now be further described by way of reference only to the following non-limiting examples. It should be understood, however, that the examples following are illustrative only, and should not be taken in any way as a restriction on the generality of the invention 30 described above. EXAMPLE 1 IDENTIFICATION OF MICROORGANISMS FROM SPUTUM SAMPLE 35 Sputum samples were obtained from pathology laboratories and diluted with water. Two microliters of these samples were used to amplify a specific conserved sequence found WO 2007/012131 PCT/AU2006/001056 -51 in eubacterial species by polymerase chain reaction (PCR). The PCR product was then used as a template for direct incorporation of the fluorescent analogue Cy5 by randomly primed polymerisation reactions Dorell et al, 2001 (Genome 5 Res. 11, 1706-15) or by post-PCR labelling. Oligonucleotide probes were designed containing unique signature sequences chosen from conserved sequences in eubacterial species and printed on micro-array slides. 10 The labelled PCR product was then hybridised to the micro array slide. The hybridisation took place under a glass cover slip in a humidified chamber submerged in a 53 0 C water bath for 30 mins. The slides were washed, dried and 15 scanned for fluorescence by using a laser-activated, confocal scanner. Background was subtracted for each spot on the scanned array and analysed by the software to give the species 20 present in the clinical sample and to advise on the appropriate treatment of the patient. Materials and methods 25 Slides: CodeLink m activated slides (GE Healthcare). Oligonucleotide probes: Oligonucleotides ranging from 17 to 24 nucleotides with a 5' amino modification and 10 T attachment at 5' end were designed. Oligonucleotides were 30 designed containing unique signature sequences in the eubacterial species' tuf gene. Spotting solution: 1M sodium phosphate buffer. Oligonucleotides dissolved in Milli-Q water at a 35 concentration of 100 pM. Final concentration of oligonucleotides in spotting solution was 25 pM and that of sodium phosphate buffer was 250 mM.

WO 2007/012131 PCT/AU2006/001056 -52 Printing: Printing of Epoxy slides was performed using MicroGrid II Compact Microarrayer (BioRobotics). 5 Target DNA: A fragment of the tuf gene was amplified using the primer pair MAtuf-F4 (forward primer, 5' KYACIGGHGTBGARATGTTC 3', SEQ ID NO.:396) and MAtuf-R5 (reverse primer, 5' GTDCGDCCRCCYTCWCGRAT 3', SEQ ID No.395). A second fragment of the tuf gene was amplified 10 using the primers MAtuf-F1 (SEQ ID No. 394) and MAtuf-R5 (SEQ ID No. 395). The primers were designed using conserved regions found in the tuf gene. The PCR conditions were 1 x 94*C, 1 min initial denaturation, 35 x 94 0 C, 30 secs/50 0 C, 30 secs/72 0 C, 30 secs, 1 x 72 0 C, 7 mins 15 final extension. PCR products were purified using the Wizard PCR Preps DNA Purification kit (Promega) prior to labelling. Labelling: Labelling was performed using the labelling 20 mixture 2mM dATP, dCTP, dGTP, 1.5mM dTTP and 0.5mM biotin dUTP. Labelling was performed overnight at 37 0 C for the product obtained using the primers MAtuf-F4 and MAtuf-R5. Direct labelling during the PCR reaction using Cy5-dUTP (GE Healthcare) was performed for the tuf 25 fragment amplified using the MAtuf-F1 and MAtuf-R5 primers. Hybridisation: Hybridisation was performed in a hybridisation chamber at 53 0 C for 30 minutes. This was 30 followed by 4 wash steps, 5 minutes each as follows: wash 1, 2 x SSC/0.1% SDS; wash 2, 0.5 x SSC/0.1% SDS; wash 3, 2 x SSC; wash 4, 4 x SSC/0.2% Tween 20. After hybridisation, the arrays were scanned using a GenePix 4000B scanner (Affymetrix). 35 Results WO 2007/012131 PCT/AU2006/001056 -53 PCR amplification of the tuf gene fragment. The size of the amplified PCR product using the primers MAtuf-F4 and MAtuf-R5 was approximately 381 base pairs (Figure 1). The primers MAtuf-F1 and MAtuf-R5 primers produced a PCR 5 amplification product of approximately 1.1 kb. Scanner outputs. The microarray successfully detected and differentiated organisms tested in this study; namely (a) Streptococcus pneumoniae; (b) Moraxella catarrhalis; (c) 10 Legionella pneumophila; (d) Staphylococcus aureus; (e) Haemophilus influenzae (Figures 2, 3, 4, 5 and 6) Discussion 15 DNA microarrays combine high-precision technology with advanced molecular biology to acquire high-throughput screening of DNA fragments. In this study, the potential of the DNA microarray technique to identify and differentiate PCR derived amplicons from five pathogenic 20 bacteria was investigated; namely, Streptococcus pneumoniae, Moraxella catarrhalis, Legionella pneumophila, Staphylococcus aureus and Haemophilus influenzae. A fragment from the tuf gene was chosen for amplification. 25 This gene is universally present in all bacterial species. Parts of this gene are highly conserved (conserved regions) whereas the rest exhibit high variation (variable regions). The conserved and variable regions were determined via multiple sequence alignment of the gene 30 using the tuf DNA sequences obtained from several different bacterial species. The conserved regions were used to design primers in order to obtain amplicons containing variable regions. These amplicons were used on a DNA microarray to detect and differentiate 35 aforementioned bacterial species. This indicates that microarray technology can be used as a WO 2007/012131 PCT/AU2006/001056 -54 method for identifying and discriminating bacterial species. The method has been proven to be highly sensitive and specific. This investigation demonstrates that bacterial tuf gene sequences amplified via PCR technique 5 could be successfully coupled with DNA microarrays to serve the above purpose in a clinical diagnostic setup. If current demands can be met, nucleic acid microarray technology will give competitive advantages over other molecular based identification methods. The rapid 10 development in this area will improve the technology and reduce the cost at the same time, making the microarray methodology attractive and competitive. Sequences 15 Nucleotide sequences of tuf genes from various microorganisms are provided in SEQ ID NOs.:1 to 11. SEQ ID NOs.:12 to 393 are signature (probe) sequences from various microorganisms, in which: 20 ABAU - Acinetobacter baumanii BCEP - Burkholderia cepacia BPER - Bordetella pertussis CABO - Chlamycophila abortus 25 CDIP - Corynebacterium diphtheriae CJEJ - Campylobacter jejuni CPER - Clostridium perfringens CPNE - Chlamydophila pneumoniae CTET - Clostridium tetani 30 EFAE - Enterococcus faecalis FNUC - Fusobacterium nucleatum HPYL - Helicobacter pylori HHEP - Helicobacter hepaticus HINF - Haemophilus influenzae 35 KPNE - Klebsiella pneumoniae LLON - Legionella longbeachiae LMON - Listeria monocytogenes WO 2007/012131 PCT/AU2006/001056 -55 LPNE - Legionella pneumophila MCAT - Moraxella catarrhalis MTUB - Mycobacterium tuberculosis MPNE - Mycoplasma pneumoniae 5 NGON - Neisseria gonorrhoeae NMEN - Neisseria meningitidis PAER - Pseudomonas aeruginosa SAUR - Staphylococcus aureus SEPI - Staphylococcus epidermidis 10 SSAP - Staphylococcus saprophyticus SMAL - Stenotrophomonas maltophilia SPNE - Streptococcus pneumoniae SPYO - Streptococcus pyogenes SMUT - Streptococcus mutans 15 SSAN - Streptococcus sanguis SMAR - Serratia marcescens VVUL - Vibrio vulnificus VPAR - Vibrio parahaemolyticus VCHO - Vibrio cholerae 20 YPES - Yersinia pestis YPSE - Yersinia pseudotuberculosis Sequences 394 and 395 are oligonucleotide primers designed against the conserved regions of tuf genes of various 25 micro-organisms. Sequences may also contain alternative bases. These are shown as follows: 30 R - A or G Y - C or T M - A or C K - G or T S - G or C 35 W - A or T H - A or C or T B - G or C or T WO 2007/012131 PCT/AU2006/001056 - 56 V - A or G or C D - A or G or T I - A base that binds to A, G, C or T

Claims

1. A method for detecting at least one microorganism in a clinical sample comprising: (a) providing a clinical sample suspected of containing one or more microorganisms; (b) releasing, isolating and/or concentrating polynucleic acids from said at least one microorganism(s) from said clinical sample, if present in the clinical sample; (c) amplifying a portion of said polynucleic acids with at least one primer pair selected from SEQ ID NO: 394 and 395 or SEQ ID NO: 396 and 395 to produce an amplified product; (d) contacting said amplified product with at least one probe or combination thereof selected from the group consisting of SEQ ID NOs:12 to 393 for a time and under conditions sufficient for hybridization to take place; and (e) detecting any hybridization which has taken place in step (d); wherein the presence or absence of hybridization is indicative of the presence or absence of said one or more microorganisms in said clinical sample.

2. A method according to claim 1, wherein the primer pairs are SEQ ID NO. 394 and SEQ ID NO. 395 or SEQ ID NO. 396 and SEQ ID NO. 395.

3. A method according to claim 1 or claim 2, wherein the polynucleic acids consist essentially of nucleotides

108-220, 393-591, 708-774, 792-816, and/or 885-945 of SEQ ID NOs.:1 to 11. 4. A method according to any one of claims 1 to 3, wherein the microorganism detected is selected from the group consisting of Bordetella species, Chlamydophila species, Haemophilus species, Legionella species, 3740347_1 DOCX 4088900 1 (GHMatters) P60284.AU.1 58 Mycoplasma species, Mycobacterium species, Staphylococcus species, Streptococcus species, Pseudomonas species, Moraxella species and Fusobacterium species, Stenotrophomonas species, Burkholderi species, Enterococcus species, Corynebacterium species and Neisseria species. 5. A method according to any one of claims 1 to 3, wherein the microorganism detected is selected from the group consisting of Acinetobacter baumanii, Bordetella pertussis, Burkholderia cepacia, Chlamydophyla pneumoniae, Corynebacterium diphtheriae, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Fusobacterium neucleatum, Haemophilus influenzae, Klebsiella pneumoniae, Legionella longbeachiae, Legionella pneumophila, Moraxella catarrhalis, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Staphyloccoccus epidermidis, Stenotrophomonas maltophilia, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus mutans, Streptococcus sanguinis, and Serratia marcescens. 6. A method according to any one of claims 1 to 5, wherein the clinical sample is a sputum sample. 7. A method for diagnosing a bacterial infection in a subject, said method comprising: a) obtaining polynucleic acids from a clinical sample taken from said subject; b) amplifying a portion of said polynucleic acids with at least one primer pair selected from SEQ ID NO: 394 and 395 or SEQ ID NO: 396 and 395 to produce an amplified product; (c) contacting said amplified product with a microarray comprising at least one probe or combination thereof selected from the group consisting of SEQ ID NOs:12 to 393 for a time and under conditions sufficient 3740147_1 DOCX AMAAA 1 (MHM-AtnlI P8078 AU 1 59 to form one or more hybridization complexes; and (d) detecting any hybridization which has taken place in step (c), wherein the presence of hybridization is indicative of the presence of bacterial infection. 8. A kit for the detection of at least one microorganism in a clinical sample, comprising: a microarray comprising at least one probe or combination thereof selected from the group consisting of SEQ ID NOs:12 to 393; and at least one primer pair selected from SEQ ID NO: 394 and 395 or SEQ ID NO: 396 and 395. 9. A kit according to claim 8, further comprising a buffer, or components necessary to produce the buffer enabling a hybridization reaction between the microarray and a polynucleic acid present in the sample, or the amplified products thereof. 10. A kit according to claim 8 or claim 9, further comprising a solution, or components necessary for producing the solution, enabling washing of the hybrids formed under the appropriate wash conditions. 3740347_ I DOCX. 4068900 1 (GHMatters) P00264.AU.1